Mississippi State University

Scholars Junction
Theses and Dissertations

Theses and Dissertations

5-1-2020

Biophysical characterization of traditional and nontraditional
equilibria in metal-biomolecular interactions
Kayla Diane McConnell

Follow this and additional works at: https://scholarsjunction.msstate.edu/td

Recommended Citation
McConnell, Kayla Diane, "Biophysical characterization of traditional and nontraditional equilibria in metalbiomolecular interactions" (2020). Theses and Dissertations. 900.
https://scholarsjunction.msstate.edu/td/900

This Dissertation - Open Access is brought to you for free and open access by the Theses and Dissertations at
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com.

Template C with Schemes v4.1 (beta): Created by L. Threet 11/15/19

Biophysical characterization of traditional and nontraditional equilibria
in metal-biomolecular interactions
By
TITLE PAGE
Kayla Diane McConnell

Approved by:
Joseph P. Emerson (Co-Major Professor/Graduate Coordinator)
Nicholas C. Fitzkee (Co-Major Professor)
Richard D. Sheardy
Debra A. Mlsna
Amanda L. Patrick
Rick Travis (Dean, College of Arts & Sciences)

A Dissertation
Submitted to the Faculty of
Mississippi State University
in Partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy
in Chemistry
in the Department of Chemistry
Mississippi State, Mississippi
May 2020

Copyright by
COPYRIGHT PAGE
Kayla Diane McConnell
2020

Name: Kayla Diane McConnell
ABSTRACT
Date of Degree: May 1, 2020
Institution: Mississippi State University
Major Field: Chemistry
Major Professors: Joseph P. Emerson, Nicholas C. Fitzkee
Title of Study: Biophysical characterization of traditional and nontraditional equilibria in metalbiomolecular interactions
Pages in Study: 145
Candidate for Degree of Doctor of Philosophy
Numerous biological phenomena occur as a result of macromolecular interactions. Metalion-biomolecule binding account for a large portion of these reactions, and unsurprisingly, a vast
amount of new research in this area is constantly emerging. Gaining insight into the
characteristics that define these interactions; including equilibrium fluctuations, metal center
formation, global stability perturbation, cooperativity, allostery, and site-specific binding are all
significant. As with all chemical reactions, biological interactions are regulated by
thermodynamics; and the development of novel tools and methods by which to study these
interactions becomes highly relevant. In this dissertation, three systems involving
macromolecular binding are studied using well established biophysical techniques in conjunction
with a critical look at appropriate uses for mathematical modeling.
The first system studied is that of the serpin plasminogen activator inhibitor-1 (PAI-1).
PAI-1 is a protease inhibitor that specifically effects fibrinolysis, or the process that prevents the
formation of blood clots, and misregulation of this enzyme leads to uncontrollable hemorrhaging.
ITC was utilized to investigate the thermodynamics of copper binding to PAI-1.

Human carbonic anhydrase II (CA) was the second system investigated. Studies were
conducted on zinc(II) and copper(II) binding to CA, a metalloenzyme responsible for acid-base
balances in the blood and the transport of carbon dioxide. Interestingly, CA binds two copper(II)
ions, one at the active site, and one at a higher affinity N-terminal site. Temperature dependent
ITC, CD and GdnHCl denaturation studies were performed to explore the impact of copper(II)
binding, particularly at the higher affinity N-terminal site.
Finally, protein binding to inorganic gold nanoparticles (AuNPs) was investigated.
AuNPS are utilized in areas of diagnostics, biological sensing and drug delivery. We studied
binding of nanoparticles to a set of six biologically relevant proteins; glutathione, wild-type
GB3, K19C GB3 (a variant at position 19), bovine CA, bovine serum albumin, and fibrinogen.
Nanoparticle-protein binding was monitored via UV-Visible extinction and polarized resonance
synchronous spectroscopy (PRS2). The UV extinction maxima wavelength shifts were fit with
two models, a Langmuir isotherm model and a mass action-derived model. The models fit the
data equally well, however, they predict very different 𝐾𝑑 values, specifically for smaller sized
AuNPs.
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CHAPTER I
INTRODUCTION
1.1
1.1.1

Thermodynamics of biomolecular interactions
Thermodynamics govern biomolecular interactions
Successful cellular operation is largely grounded in the extreme specificity of molecular

interactions; specifically the ability of and affinity for two matched partners to interact and carry
out a precise function. Understanding the molecular properties that define the affinity of two
species interacting is crucial to our understanding of all biomolecular interactions, including why
cofactors are important, how drugs are metabolized, and how proteins perform their intended
functions. Understanding the properties that define affinity also offer much information in
regards to disease states; the causes of which, and in turn the mediation of, can be attributed to
the maintenance of normal biomolecular pathways.
Biomolecular interactions that include biomolecule-metal binding account for a large
population of interactions in biology. Approximately 47% of structurally defined proteins require
metal ions and of those, 41% possess metals at their catalysis site. 1 These metals are categorized
as redox-inert or redox-active. The most common metal ions are redox-inert, such as magnesium
and zinc, which are used to stabilize negative charges in metal-containing biomolecules as well
as to act as Lewis acids to activate substrate binding at the active site of enzymes.2 The most
common metal ion in the redox-active group is iron, and is used as both a Lewis acid and a redox
center for the catalysis of redox reactions.2
1

Generally, biomolecular interactions are governed and regulated by thermodynamics,
where the binding affinity constant, K 𝑎 , is the measure of product and reactant concentration at
equilibrium (Equation 1.2). An equilibrium between biomolecule (B) and metal (M) form a
biomolecule-metal complex (BM) that is defined by the ratio of the free species to the species in
complex. An example of a simple binding equilibrium is shown in Equation 1.1.

(1.1)

Ka is the common notation used to describe the equilibrium constant for an equilibrium
expression. Ka can be calculated by the activities of the related species at equilibrium.
Commonly under biologically relevant conditions, the activity of these entities can be associated
with their relative concentrations. Often in biological sciences, Ka is represented as its reciprocal,
Kd. Unlike Ka, Kd is commonly expressed using units of concentration, with larger values
reflecting weaker binding and smaller values reflecting tighter binding.

(1.2)

Given Ka at a chosen temperature, the change in the standard Gibbs free energy of
binding can be calculated (Equation 1.3).3

(1.3)

2

In this equation, R is the gas constant and T is the absolute temperature. If temperature
and pressure are will defined, ΔG° can be further dissected into two contributing terms, the
change in enthalpy of binding, ΔH°, and the change in entropy of binding, ΔS°. The relationship
between these terms is described in Equation 1.4.

(1.4)

For biomolecule-metal binding, thermodynamic terms can span between favorable and
unfavorable contributions where the overall energy, ΔG°, is the driving force of the process.
Loss of biomolecule-water and metal-water interactions are disfavored (ΔH>0) and the gain of
biomolecule-metal and water-water interactions are favorable (ΔH<0). For entropic
contributions, the release of bound water (ΔS>0), biomolecule loss of rotational and translational
entropy (ΔS<0), and an increase in biomolecule rigidity (ΔS<0) are the major contributions.
Overall, for biomolecule-metal binding to be favorable, the combination of the enthalpic
contributions and entropic contributions must yield a negative free energy (ΔG<0). In order for
this to occur, favorable enthalpic contributions (ΔH<0) from biomolecule-metal binding and
favorable entropic contributions from the release of bound water (ΔS>0) must overcome
unfavorable entropy loss as a result of an increase in biomolecule structure (ΔS<0) and the loss
of the enthalpic interactions for biomolecule-water and metal-water (ΔH>0).

3

Figure 1.1

Energy profile for biomolecule-metal interaction

Energy profile for a biomolecule-metal interaction with the change in energy, ΔE, denoted in
blue and is defined as the difference between the reactant and product energies.

4

1.1.2
1.1.2.1

Perturbation allows deconvolution of interaction affinity
Hess’ Law
Studying the thermodynamics of biomolecular interactions brings with it a complex

interweaving of many thermodynamic contributions that comprise the whole of the system. In
order to parse or unravel each of the contributions into their respective pieces, we can compare
very closely related systems and observe the apparent differences. This method is referred to as
the perturbation method and its use allows the cancellation of known thermodynamic
contributions in order to elucidate specific contributions that dominate these processes. The
simplest example of this is through the use of Hess’ Law. Hess’ Law allows for the calculation of
thermodynamic terms that cannot be directly measured by the simple summation of
thermodynamic values associated with reactions that can be measured. Building on Hess’ Law
allows for the use of enthalpies of formation to be used to calculate the ∆𝐻°𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 through
Equation 1.5.

(1.5)

This addition of thermodynamic terms is comprehensive and can also be applied to free
energy and entropy as well.4 For free energy we find that:

(1.6)

5

Because entropy is measured in absolute terms and not as a function of the individual
elements in a given reaction, the equation is changed to reflect absolute entropies as shown in
equation 1.7.

(1.7)

Extending these concepts to biomolecular systems allows for the dissection of the
thermodynamic terms associated with biomolecule-metal binding by subtracting out the
thermodynamics associated with other interactions, including metal-solvent, solvent-solvent, and
biomolecule-solvent contributions. For an example system, consider a single metal binding to a
single biomolecule. A collective ∆𝐻 of the process can be experimentally measured, as well as a
series of control experiments in order to parse the ∆𝐻 from the individual contributions. By
subtracting contributions to ∆𝐻 from the loss of biomolecule-solvent interactions, (BS), and loss
of metal-solvent interactions, (MS), we can determine enthalpic contributions that more
accurately describe biomolecule-metal formation, (BM) (Table 1.1).

6

Table 1.1

Hess’ Law for protein-ligand interaction

Reaction

Heat

𝐵 + 𝑀 + 𝑀𝑆 + 𝐵𝑆 ⇌ 𝐵 + 𝑆 + 𝑀 + 𝐵𝑀

∆𝐻𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙

𝐵𝑆 ⇌ 𝐵 + 𝑆

−∆𝐻𝐵𝑆

𝑀𝑆 ⇌ 𝑀 + 𝑆

−∆𝐻𝑀𝑆

𝐵 + 𝑀 ⇌ 𝐵𝑀

∆𝐻𝐵𝑀

Experimental enthalpy values can be broken down into contribution from loss of biomoleculesolvent interactions (BS) and loss of metal-solvent interactions (MS) to yield enthalpic
contributions that more accurately describe biomolecule-metal complex formation (BM).

7

1.1.3

Biomolecular solvation thermodynamics
In biomolecular interactions, major enthalpic contribution results from the making and

breaking of non-covalent bonds or interactions. These non-covalent interactions are
predominantly hydrogen bonding, but commonly also include van der Waals, dipole-dipole, and
electrostatic interactions. Ligand binding in the absence of solvent is generally considered to be
entropically unfavorable as rotational and translational energy of the ligand is lost during
biomolecule-ligand complexation. However, for biomolecule-metal interactions, loss of
rotational and translational energy is of no consequence and the change in enthalpy of binding is
directly related to the strength of metal binding relative to the strength of metal-solvent
interactions. Conversely, the change in entropy of binding is characterized by the gain in
solvation entropy due to metal ion desolvation in relation to the loss of biomolecular
conformational entropy (torsional restriction and loss in degrees of freedom).
Reorganization of solvent interactions upon ligand binding are in general major sources
of enthalpic and entropic contributions. Water molecules hydrogen bond to each other as well as
to solvent accessible residues in biomolecules.5-8 This hydrogen bonding network between the
solvent and the biomolecule is highly stabilizing and as such is often enthalpically favorable.
Non-polar residues and metals do not form strong hydrogen bonding networks and water is
believed to order these regions at the protein surface in order to minimize the energy requirement
for long-distance and misalignment of hydrogen bonds that occur around the regions.9
Alternately, some non-polar protein surface residues are not exposed to bulk solvent and
therefore water molecules are not able to penetrate and form hydrogen bonding networks. These
pockets of non-polar residues have higher entropy than bulk solvent.10-12

8

1.1.4

Conformational Entropy
The formation of hydrogen bonding networks and other interactions arrange polar bulk

solvent around non-polar residues in such a way as to stabilize a biomolecule into an
enthalpically favorable conformation. However, the number of conformations that are
enthalpically favorable can be vast and therefore another entropic contribution can be dissected,
that of conformational entropy. Before conformational enthalpy can be properly discussed it’s
important to first visit the meaning of differing biomolecular conformation or microstates.
Proteins can adopt many types of conformations based upon primary, secondary, and
tertiary structural components. Conformational entropy is the entropy for a number of
conformations a particular biomolecule can be associated with. Conformational entropy changes
can be estimated for a number of conformations by first discretizing the biomolecule into a
predetermined number of conformational states. The number of states can be determined by
enumerating structural possibilities, e.g. by counting energetically equivalent backbone dihedral
angles and amino acid side chain rotamers in proteins. 13-15 Three torsion angles are of
importance, rotation around the N-C′ bond (ω), rotation around the C′-Cα bond (ψ) and the
roation around the Cα-N bond (ϕ) connecting two amino acids. Planarity seen in peptide bonds
typically restricts ω to a rotation of 180° in the trans conformation and 0° in the cis
conformation.16 Cis conformations for ω are rare, due to steric hindrance of the side chains (with
proline residues as the exception) and the majority of peptide bonds adopt a trans
conformation.17 These structural possibilities are used to calculate and define the number of
degrees of freedom for each state and in turn, the conformational entropy for each state is
calculated based on the probability that the protein will adopt any one particular conformation.

9

Figure 1.2

Protein backbone representation

In a protein backbone, three torsion angles connecting two successive amino acids are of
importance. Rotation around these angles are classified as N-C bond rotations (ω), C-C bond
rotations (ψ) and C-N bond rotations (ϕ).

10

1.1.4.1

Further applications for conformational entropy
Conformational entropy can further be used to estimate the number of resides that fold

upon binding of a biomolecule complex and this was notably accomplished by Spolar and
Record in 1994.18 In the study, protein-DNA binding experiments were surveyed. The entropy
changes associated with rigid body associations and those associated with conformational
changes upon protein-DNA interactions were uncoupled to show individual entropic
contributions from effects of changes in conformation of the amino acid chain, loss of translation
and rotational energy, and more specifically the entropic contributions attributed to protein
°
folding or the burial of non-polar side chains. The entropic association contribution, ∆𝑆𝑎𝑠𝑠𝑜𝑐
, was

obtained by studying the coupling of local residue folding to binding and its association with
large negative changes in heat capacities upon protein-ligand and protein-DNA binding. What
was ultimately found was that DNA structures do not alter upon complexation, but rather
proteins fold around the DNA as it binds. The large negative heat capacity associated with that
complexations is from the increase in overall structure of the protein-DNA complex and the
entropy term associated can be used to calculate the number of residues that fold upon binding.
The enthalpies of binding for at least three temperatures can be used to determine the heat
capacity of the interaction by recalling that at constant pressure, the enthalpy can be expressed as

(1.8)

where n is the number of moles of the molecule and 𝐶𝑝 is the heat capacity. Consequently, for a
reaction, enthalpy is expressed by equation 1.9.

11

(1.9)

By plotting enthalpy as a function of temperature, the slope of the linear fit is the change
in heat capacity. An example of an enthalpy versus temperature plot yielding a linear fit is
illustrated in Figure 1.3.

12

Figure 1.3

Heat capacity plot

The change in heat capacity can be determined by the slope of the linear fit of the change in
enthalpy (ΔH) versus temperature (K).

13

Spolar and Record expanded ideas regarding conformation entropy by breaking down the
entropy changes obtained from the change in heat capacities by separating the entropy terms into
three specific contributions (Figure 1.10).

(1.10)

The three entropic contributions are: 1) from the hydrophobic contribution associated with
scaling the size of the reaction, including the solvent, ∆𝑆𝐻𝐸 2) from the rigid body loss of
rotational and translational entropy, ∆𝑆𝑟𝑡 (this can be calculated), and 3) from the entropy loss as
the protein becomes more structured as a result of the conformational change, ∆𝑆𝑐𝑜𝑛𝑓 . The final
term contains information about to what degree the protein is folding and from this term
specifically, how many residues are becoming more structured or folding upon protein-ligand
binding can be determined.

∆𝑆𝐻𝐸 is estimated directly from the heat capacity change of the system and is
proportional to the nonpolar surface area of solvent exposed residues. We know this due to work
by Baldwin, et al, who showed that the entropic contributions of hydrophobic effects are
essentially zero at 386 K.5 Therefore, the entropy from hydrophobic effects can be calculated at
other temperatures from this relationship via

(1.11)
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We now know that at some temperature, 𝑇𝑠 , the hydrophobic contribution for the protein-ligand
°
(𝑇𝑠 ) as a
complexation will reach a zero value and equation 1.10 can be rewritten to reflect ∆𝑆𝑓𝑜𝑙𝑑
°
(𝑇) as denoted the specific experimental temperature
zero value while maintaining ∆𝑆𝑓𝑜𝑙𝑑

dependence term.

(1.12)

By rearrangement the 𝑇𝑠 term becomes

(1.13)

where the total entropy change for the complexation is simplified to

(1.14)

For an entropy change to be zero at 𝑇𝑠 , ∆𝑆𝑐𝑜𝑛𝑓 has to be large in order to signify a large
entropy change for the entire complexation and therefore the term must be consistent with a
change in conformational entropy. If a large overall folding entropy is observed, the division of
∆𝑆𝑐𝑜𝑛𝑓 by the average change in entropy per residue (-5.6 ± 0.5 a.u.) experimentally determined
from 13 protein folding experiments, yields an ℜ𝑡ℎ term that is equal to the number of residues
that fold upon protein-ligand binding.18 Further, ∆𝑆𝑟𝑡 , the rigid body rotational and translation
entropy loss was determined to be -0.05 a.u.18 Equation 1.14 can then be rewritten to reflect these
additions and is shown in equation 1.15.
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(1.15)

Solving for the ℜ𝑡ℎ term then yields equation 1.16.

(1.16)

This complicated and sophisticated unlinking of entropy terms from heat capacity
changes measured for protein-ligand binding was tested for 10 protein-DNA binding systems and
was shown to be successful at predicting the number of residues that fold upon binding. This is a
significant advancement and will be extremely supportive in further studies where protein-ligand
binding and the number of residues that fold upon binding are central to the function and
dysfunction of macromolecules in the presence of differing ligands.
1.2

Mathematical modeling for biomolecular interactions
Modeling can be used to describe biomolecular interaction data obtained via

experimentation. Binding curves from calorimetric or other experimental data can be fit using
several types of models and values for expressions such as binding affinity, number of binding
sites and thermodynamic terms can be obtained. 19-26 There are many models that can be utilized
to fit binding data but the most commonly used and most simplistic is the Langmuir model.
Other less common but no less powerful are the mass action model and the McGhee von Hippel
model, which add further parameters to explain comparatively more complex phenomena. The
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models discussed below have been made uniform and reflect general protein (P)/macromolecule
(M) and ligand (L) interaction terms.
1.2.1

Langmuir model
The Langmuir model describes biomolecular-ligand interactions by utilizing the

assumption that the ligand behaves as an ideal gas would at isothermal, or constant temperature,
conditions.27 In this model, adsorption is the binding of the ligand and desorption is the reverse
of that binding process. The Langmuir model assumes that adsorption and desorption are
reversible processes and that the biomolecule is an ideal solid surface containing N number of
independent, identical binding sites.27 The isotherm initially intended to describe the equilibrium
process when ionic or covalent bonds are formed between the biomolecule and the ligand, where
one binding layer is achieved. The Langmuir model also assumes that the fractional surface
bound is directly proportional to the desorption rate and that the absorption and desorption rates
are equal to each other when the system is at equilibrium. The Langmuir model is generally an
ideal model for small molecule interactions but when used in larger and less ordered systems is
not as useful. Nevertheless, many other models and the adsorption theory itself is built upon this
model and as such it is usually the first model used to describe biomolecular-ligand binding. The
model can be represented by equation 1.17.

(1.17)

where 𝑋̅ is the degree of binding which equals the concentration of bound ligand divided by the
total macromolecule concentration. 𝐿𝑓𝑟𝑒𝑒 is the concentration of free ligand, and 𝐾𝑑 is the
17

dissociation constant. Using this model, the independent parameter is the free protein
concentration and often this is assumed to be the total protein concentration. This model
therefore has significant drawbacks, one of which is the requirement that the free ligand
concentration is known.
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Figure 1.4

Langmuir model fit

An example of a fit using the Langmuir model. 𝑋̅, or bound complex is plotted again the ligand
concentration. Individual points represent sample data and the fit yields a 𝐾𝑑 value for the
macromolecule-ligand interaction.
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1.2.2

Mass action model
A more useful model could be the one that includes additional, measurable data for free

and bound concentrations and is derived from mass action. Mass action models are governed by
the law of mass action, in which the rate of the reaction is proportional to the concentrations of
the reactants.28 This proposes that for a reaction in equilibrium, the concentration ratio of
reactants to products is constant. This distinction offers a better model for ligand binding, as the
equilibrium constant is not dependent on free ligand concentrations but rather on the total
concentrations of the ligand and macromolecule. Mass action models can also be adapted to fit
the needs of the system and can include these distinctions, as well as parameters such as the
number of binding sites per macromolecule. For a traditional protein-ligand interaction, such as
when the ligand is a metal ion and the protein is an enzyme, one or possibly two ligand binding
sites per protein is typical. For systems of nanomaterials with a high stoichiometry of binding,
the protein itself is the ligand and the nanomaterial is the macromolecule. The nanomaterial will
then have many possible binding sites, N, and can be estimated by the radius of gyration of the
protein and the size of the nanomaterial.29

(1.18)

𝑅𝐴𝑢𝑁𝑃 is the radius of the nanoparticle and 𝑅𝐺 is the protein radius of gyration. The radius of
gyration for any given protein can be calculated with the use of the protein crystal structure via
equation 1.19.
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(1.19)

In equation 1.19, N is the total number of non-hydrogen atoms, ⃑⃑⃑
𝑋𝑖 is the position of atom i in the
structure, and 𝑋 is the geometric center of the molecule. From this, an approximate size of a
proteins globular structure (in Angstroms) can be calculated.

With the use of equations 1.17-1.19, a model can be derived:

(1.20)

Where 𝐿𝑏𝑜𝑢𝑛𝑑 , 𝐿𝑓𝑟𝑒𝑒, 𝐿𝑡𝑜𝑡 equals the bound, free and total ligand concentrations. 𝐾𝑑 is the
𝐿
dissociation constant. 𝑀𝑡𝑜𝑡 is the total macromolecule concentrations. 𝑋̅ = 𝑏𝑜𝑢𝑛𝑑
and is equal to
𝑀
𝑡𝑜𝑡

the degree of binding, 𝐿𝑓𝑟𝑒𝑒 = 𝐿𝑡𝑜𝑡 − 𝑋̅ ∙ 𝑀𝑡𝑜𝑡 . 𝑁 is equal to the number of identical,
independent binding sites per macromolecule.
1.2.3

Scatchard equation
The Scatchard model is another way to represent equilibrium binding.30 The Scatchard

equation is given by
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(1.21)

𝑋̅

When [𝐿] versus 𝑋̅ is plotted, a linear fit yields an x-intercept equal to 𝑛 (the reaction
1

stoichiometry), a y-intercept equal to 𝑛𝐾𝑎 , and a slope equal to −𝐾𝑎 or − 𝐾 .
𝑑
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Figure 1.5

Scatchard Plot

An example Scatchard plot, showing that in a plot of bound macromolecule over free ligand
concentration versus bound macromolecule, the y-intercept is equal to the binding stoichiometry
multiplied by the association constant and the slope is equal to the negative association constant
or the negative inverse dissociation constant.
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1.2.4

McGhee von Hippel model
The Langmuir model, mass action model and Scatchard model assume that every

interaction surface is energetically identical, meaning that all sites have the same binding energy
for a particular ligand and that ligand can absorb at readily defined sites that can only contain
one ligand. Furthermore, the assumption is made that the binding energy at one particular site is
entirely independent of the presence or absence of binding at any other site. This is a downfall
that becomes of interest particularly in lattice-type binding where the probability of binding at
one site is adversely affected by the binding at other sites. The use of Scatchard plots to
determine possible energy differences in binding sites is especially useful. Scatchard plots can be
constructed to visualize any curvature that may be indicative of competition for binding site
location, especially toward saturation where the depletion of binding sites becomes increasingly
entropically unfavorable31. A concave-up curvature of the Scatchard plot would indicate a
resistance in saturation that could affect accurate determination of the dissociation constant for
the interaction and use of the McGhee von Hippel model can be used to account for this
behavior.31 An example of a Scatchard plot and concave up curvature is shown in Figure 1.6.
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Figure 1.6

Scatchard plot with competitive binding

An example Scatchard plot illustrating a linear correlation for a non-competitive binding event
shown as a solid black line and a competitive binding event shown as a dashed black line. The yintercept is equal to the stoichiometry of the binding event divided by the association constant
and the slope is equal to the association constant.
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In the event of a binding interaction that shows the concave up nature seen in Figure 1.6,
the data cannot be fit accurately using the general Scatchard equation and must be fit using the
McGhee von Hippel equation. The McGhee von Hippel model calculates the ligand binding
behavior of an infinite lattice by starting with the simple equation describing the relationship
between the length of the lattice and a ligand affinity for the lattice (Equation 1.22).

(1.22)

̅𝑓𝑙 is the number of free ligand site per 𝑙 length of
In this equation, 𝑋̅ is bound complex, 𝑁
lattice and k is the microscopic dissociation constant for the one site ligand-lattice interaction.
Microscopic dissociation constants, 𝑘, should not be confused with a standard dissociation
constant, 𝐾𝑑 . The microscopic dissociation constant describes the dissociation constant for
individual binding sites while the standard dissociation constant is an overall term for the affinity
̅𝑓𝑙 , one first calculates the probability, 𝑝𝑙 , that starting at any
of a particular ligand. To calculate 𝑁
point on the lattice, 𝑙 consecutive units are unbound. The probability can then be used to
calculate the average number of free ligand binding sites per length 𝑙 of lattice. Figure 1.7
illustrates four possible binding scenarios for a lattice with an N value of four and 𝑙 of 1.

The probability, 𝑃𝑙 can be expressed as shown in Equation 1.24.

(1.23)
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In Equation 1.3, 𝑃𝑙 is the probability that a randomly selected binding site on the lattice is
unoccupied and 𝑃𝑓𝑓 is the probability that a free binding site on the lattice is followed by a
second free binding site. The fraction of occupied binding sites is expressed as Equation 1.24.

(1.24)

And the fraction of unoccupied sites can be expressed as Equation 1.26.

(1.25)

Therefore, the probability of a binding site being occupied or unoccupied can be shown by
Equations 1.27 and 1.28, respectively.

(1.26)

(1.27)

Substitution and rearrangement yields a final term for the probability of total binding sites
preceded by another free binding site (Equation 1.40).
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(1.28)

Substituting for 𝑃𝑓𝑓 , we then find the final McGhee von Hippel equation expressed as

(1.29)

Employing this equation, utilitzing experimental 𝑋̅ and [L] terms, N and k can be fit. Fits
obtained throught the use of this model can then be illustrating by utilizing a Scatchard plot
similiar to the one shown in Figure 1.8.32
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Figure 1.7

Lattice-ligand binding

A-D indicate four possible binding scenarios for a lattice structure with 𝑙 = 1 and 𝑁 = 4, denoting
one ligand binding per length at four possible binding sites. Figure adapted from Cantor, C. R.
and Schimmel, P. R, 1980.32
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Figure 1.8

Scatchard plot for lattice-ligand binding

Scatchard plot for the determination of 𝑙 and N values using the McGhee von Hippel equation.
The x-intercept is equal to the number of binding site divided by the number of binding sites per
length of lattice, the y-intercept is equal to the number of binding sites divided by the
microscopic dissociation constant and the slope of the line is the binding sites per length of
lattice (the larger the number of binding sites per length of lattice, the steeper the deviation from
the 𝑙 = 1 line). Figure adapted from Cantor, C. R. and Schimmel, P. R, 1980.32
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1.2.5

Predicting the temperature dependence of binding: The van’t Hoff Equation
The van’t Hoff model is based upon the van’t Hoff equation that further the equilibrium

constant, K, to changes in temperature given enthalpy changes, ΔH°, of a given interaction.33, 34
Under standard conditions, the van’t Hoff equation can be represented as:

(1.30)

Assuming a constant enthalpy change over a temperature range, and integrating both
sides, we can rewrite the van’t Hoff equation as:

(1.31)

With the addition of a defined temperature range, the equation can be further rewritten to:

(1.32)

Van’t Hoff plots are especially useful as they can be used to effectively relate changes in
binding equilibrium at different temperatures to a ΔH° term. Plainly, any plot of ln 𝐾 versus T
can be fit to yield an enthalpic term from experimentation that cannot or does not have the
capability to measure enthalpy directly.
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Figure 1.9

van’t Hoff plot

A van’t Hoff plot can be used to estimate enthalpy and entropy changes for ligand binding. A
linear fit of a plot of ln(Keq) versus 1/T will yield a line with a y-intercept of ΔS°/R and a slope
of ΔH°/R.

32

1.3

Methods for studying biomolecular interactions
Biomolecular interactions are examined via the use of many different methods. No one

method is capable of giving all the information for a system under study and therefore the use of
multiple methods in conjunction is the best approach for gathering information about the nature
of these types of interactions. Each method separately has advantages and drawbacks. Method
and experimental selection therefore play a large part in obtaining quality data. For biomolecular
interactions in particular, the following methods are commonly employed.
1.3.1

Calorimetry
It is well known and previously described that protein stabilization, including the

stabilization of bound complexes, are governed by strict thermodynamic principles. Solvent
interactions are relatively small heat effects that are not able to be measured using methods such
as spectroscopy. Calorimetry was the outcome of the desire to measure these interaction heats.35
Two methods are popularly employed for this, isothermal titration calorimetry (ITC) and
differential scanning calorimetry (DSC).
1.3.1.1

DSC
DSC allows for a full thermodynamic profile of a given biomolecule in solution to be

obtained. DSC measures the partial specific heat capacities, 𝐶𝑝 , at constant pressure for a chosen
temperature range. Enthalpy and entropy changes are calculated via the change in heat capacity
of the macromolecule as a function of temperature change (equations 1.30 and 1.31).

(1.33)
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(1.34)

∆𝐶𝑝 can be divided into two contributing terms

(1.35)

that describe the transition peaks and the baseline shift that can be seen in a typical thermogram.
The melting temperature, 𝑇𝑚𝑒𝑙𝑡𝑖𝑛𝑔 , is found at the apex of the transition peak, and at this point
the folded and unfolded states are in equilibrium and Δ𝐺° = 0.
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Figure 1.10

DSC thermogram

Example thermogram illustrating the molar heat capacities of the unfolded and folded states
(shown in blue), the change in heat capacity (shown in green) and the melting temperature of a
sample protein (shown in red).
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Thermal unfolding of proteins can be modeled as a two-state transition in which the
folded structure unfolds spontaneously and quickly, meaning that only in the temperature range
of the curve are both folded and unfolded states present. 36 Modeling the curve compares the
transition enthalpy obtained from integration of the area under the curve with an enthalpy
calculated using the van’t Hoff equation. If the two values are comparable, then the transition is
indeed two-state and intermediates are solidified to be of no consequence.36 The transition
enthalpy of the curve obtained experimentally can be shown as

(1.36)

where ∆𝐶𝑝,𝑇𝑟𝑎𝑛𝑠,𝐸𝑥𝑝 (𝑇) is the transition peak value above the value for the baseline,
∆𝐶𝑝,𝐵𝑎𝑠𝑒,𝐸𝑥𝑝 (𝑇). For protein unfolding, ∆𝐶𝑝 is large and positive and the van’t Hoff equation
calculates the enthalpy and temperature dependent equilibrium constant between the folded and
unfolded states. 37, 38

(1.37)

1

Equation 1.37 describes the slope of a van’t Hoff plot of ln 𝐾 versus 𝑇 . For a two state transition
(1.38)

the equilibrium constant can be expressed as

36

(1.39)

where U(T) and F(T) are the equilibrium concentrations of folded and unfolded species at
equilibrium at a given temperature. If the van’t Hoff calculated enthalpy and the experimental
enthalpy are not comparable, the assumption of a two-state model is null and more complex
modeling in addition to further experimental investigation is required. If the enthalpies are
comparable, the transition is assumed to be two-from equation 1.39, Gibbs free energy and
subsequently entropy can be calculated for the unfolding. DSC alone does not give information
regarding biomolecular binding interactions, but comparisons of unfolding curves for unbound
biomolecules and metal-ion bound biomolecules could give information regarding overall
stability of bound versus unbound macromolecular species.
1.3.1.2

ITC
Isothermal titration calorimetry can be used to determine the enthalpy change,

equilibrium constant and binding stoichiometry of a macromolecule-ligand complex. An ITC is
comprised of a reaction cell and a titrator, with the cell commonly holding the macromolecule
and the titatrator the ligand. The ligand is titrated in small, constant volumes and the amount of
power that is required to maintain constant temperature between the reaction cell and an internal
reference cell is recorded. The enthalpy of binding is determined by integrating the power curve
over time. The heat for each injection is

(1.40)
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where the change in enthalpy per for each injection, 𝑗, equates the quotient of the injection heat,
𝑞𝑗 , the volume, 𝑣, of the cell contents and the change in the concentration of the bound ligand for
the injection, ∆[𝐿𝑖𝑔𝑎𝑛𝑑𝑗,𝑏𝑜𝑢𝑛𝑑 ]. 35
By repeating the titration at several temperatures, a heat capacity term can also be
obtained, where the change in heat capacity is equal to the partial derivative of the change in
enthalpy over temperature.

(1.41)

Fitting of the curve also will yield an equilibrium term, 𝐾𝑎 , that can be used to calculate a
free energy change and then an entropy change at a given temperature (equations 1.3 and 1.4).
Lastly, factoring in the concentration of the macromolecule and ligand, a stoichiometry, 𝑛, for
the interaction can be obtained.
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Figure 1.11

ITC Thermogram

ITC curves generated from a set of injections. A) Raw ITC thermogram. B) ITC thermogram
corrected for concentration and displaying integrated enthalpy. The difference in heat, ∆𝐻, is
represented in blue, the best fit line for the injection points is shown in red and the stoichiometry
is shown in green.
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1.4

Overview of works presented in this dissertation
In this dissertation, three metal-biomolecule equilibria systems will be discussed. The

thermodynamics, mathematical modelling and instrumental methods described in this chapter
will be utilized to characterize the binding equilibria seen for each of the systems under study.
1.4.1

Chapter 2: Resolving distinct molecular origins for copper effects on PAI-1
PAI-1 is the serpin plasminogen activator inhibitor-1 that is responsible for specific and

rapid inhibition of fibrinolytic proteases required to maintain hemostasis. Active PAI-1 is
inherently unstable and easily converts to a latent, inactive form. Binding of the glycoprotein
vintronectin increases the stability of the active form of PAI-1. Binding experiments of PAI-1 to
vitronectin in the presence of transition metals, such as copper(II), were performed to better
understand the effects of copper(II) on wild-type and mutant PAI-1 stability. ITC was utilized to
investigate the thermodynamics of copper binding and identification of a copper(II)-binding site
involving two histidines at positions 2 and 3 were shown to stabilize PAI-1 to a greater extent
than vitronectin alone.
1.4.2

Chapter 3: Impact of thermal stability of proteins upon cupric ion binding: A case
study of Cu(II) binding to human carbonic anhydrase II
Human carbonic anhydrase (CA) is a well-studied, very stable zinc-containing

metalloprotein that has been shown to be a valuable model system for biomolecular binding
studies, specifically those involving metal ion coordination. CA stability has historically been
attributed to a zinc(II) ion coordination at its active site. However, the zinc(II) ion can be readily
removed from CA using a Zn2+ chelator to generate a reasonably stable, metal-free form of CA
(apo-CA). Apo-CA can be remetallated with copper(II) to form Cu-CA and interestingly has
been shown to contain two thermodynamically distinct copper(II) binding sites. The higher
40

affinity site is located at the N-terminus and the second, lower affinity site is located at the active
site of the protein. Temperature dependent ITC studies were performed to explore the impact of
copper(II) binding, particularly at the higher affinity N-terminal site. CD and fluorescence
denaturation studies utilizing GdnHCl were also performed to probe the stability of the apo-,
zinc(II) and copper(II) form of CD. Together, the data present a greater understanding of how
metal-binding induced conformational entropy changes play a role in protein stability.
1.4.3

Chapter 4: Thermodynamics of nanoparticle protein-surface interactions
The range of applications for the use of gold nanoparticles (AuNPs) has been rapidly

growing and now includes such areas as diagnostics, catalysis, drug delivery and biological
sensing. In this work, we examine the thermodynamic consequences of protein-nanoparticle
binding using spectroscopic approaches. We monitored binding using UV-Vis spectroscopy for
six proteins chosen based on their differing size and chemical properties bound to both 15 nm
and 30 nm citrate-coated AuNPs. UV-Visible extinction and polarized resonance synchronous
spectroscopy (PRS2) were used to monitor binding. The UV extinction maxima shifts with
increasing protein concentration until saturation of the AuNPs occurs, and the wavelength shift
was fit with two models: a Langmuir isotherm model and a mass action-derived model. Both
models fit the data equally well; however, the models predict very different 𝐾𝑑 values for 15 nm
AuNPs. The PRS2 data monitor changes in scattering cross section size as protein concentration
is increased, and an overlay of binding curves built from both the UV extinction maxima shift
and the calculated cross section obtained from PRS2 scattering data are in quantitative
agreement. Together, the data suggest two-state binding is sufficient to describe the initial
adsorption process. Moreover, for the proteins studied, AuNP curvature is shown to play little
role in protein adsorption, with protein type and size showing to be the major contributing factor.
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CHAPTER II
RESOLVING DISTINCT MOLECULAR ORIGINS FOR COPPER EFFECTS ON PAI-1
*Reprinted from Joel C. Bucci, Carlee S. McClintock, Yuzhuo Chu, Gregory L. Ware,
Kayla D. McConnell, Joseph P. Emerson & Cynthia B. Peterson. “Resolving distinct molecular
origins for copper effects on PAI-1.” Journal of Biological Inorganic Chemistry 22, 1123–1135
(2017). Copyright © 2017 Springer Nature
2.1

Introduction
Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin)

responsible for controlling blood flow, and thus is subjected to strict regulation at the genetic as
well as protein level.1 PAI-1 inhibits tissue type (tPA) and urokinase (uPA) plasminogen
activators (PAs).1 Inhibition of the PAs limits the amount of activated plasmin at a site of injury
or within the extracellular compartments, and in turn controls physiological processes including
hemostasis, extracellular matrix turnover, and cell adhesive/migratory properties.2-5 Removal of
PAI-1 results in compromised wound healing and mild bleeding states due to lack of control of
the fibrinolytic components.6, 7 At the same time, excessive levels of PAI-1 result in
atherosclerosis, fibrosis in several tissue types, inflammation, metabolic syndrome, and cancer. 812

PAI-1 utilizes a solvent-exposed loop characteristic of serpins termed the reactive center
loop (RCL) shown in Figure 2.1.13 The RCL contains the same scissile bond that the PAs target
in their natural substrate, plasminogen.13 The inhibitory mechanism of PAI-1 mirrors the process
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of peptide bond cleavage by serine proteases until the final step, in which the acylated RCL
inserts into the protein body, translocating the protease with a highly distorted active site to the
opposite pole of the inhibitor.14 Among serpins, PAI-1 is unique due to its inherent metastability
in the active form.15 PAI-1 has a half-life of approximately 1-2 hours, then spontaneously
undergoes a significant structural rearrangement to an inactive, latent form that can no longer
inhibit proteases (Figure 2.1).16
A directed sequence of steps accounts for this conversion to the latent structure, in which
the uncleaved RCL must pass through the gate region loops (s3C-s4C, s3B-hG) before inserting
in between the shutter region strands (s3A and s5A). 17-19 For full RCL peptide insertion to occur,
helix F (hF) covering the lower part of the shutter must be temporarily displaced.20 An area
denoted the flexible joint region (hD, hE, s1A) is important for protein-protein interactions, most
notably with another glycoprotein, vitronectin (VN).21 VN binds to PAI-1 with high affinity (Kd
~ 0.1 nM) to localize and stabilize PAI-1 in the active form.22, 23
Several factors influence the rate at which PAI-1 converts to the latent form, including
ligands, post-translational modifications, pH, and protein dynamics.24-29 Protein dynamics play a
role in the latency process, whereby conditions that stabilize PAI-1 decrease protein dynamics,
and those that destabilize PAI-1 increase protein dynamics.29 Furthermore, hydrogen-deuterium
exchange mass spectrometry (HDX-MS) has revealed local unfolding events within the
hydrophobic core of PAI-1 that are hypothesized to be on the path to the latent state.30 Ligands
such as VN, antibodies, and RNA aptamers stabilize PAI-1 to varying degrees; these ligands also
restrict PAI-1 dynamics.24, 25, 28, 31, 32 Metal ion ligands such as copper have a particularly
interesting effect on the rate of PAI-1 latency in the presence and absence of VN, as well as the

46

isolated N-terminal somatomedin B (SMB) domain.28 Copper binds to PAI-1 with high affinity
(Kd ~ 0.09 μM), resulting in significant acceleration in the rate of latency
conversion.33
However, in the presence of both VN (or the isolated SMB domain) and copper, PAI-1 is
further stabilized compared to binding of VN or SMB alone. 24 HDX-MS experiments determined
that addition of copper destabilizes PAI-1 by localized increases in protein dynamics, whereas
the combination of copper and SMB binding results in decreases in dynamics within the same
regions of PAI-1.29
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Figure 2.1

PAI-1 exists in an active and latent conformation

The structure of the active form of PAI-1 (PDB entry 3Q02) and the latent form of PAI-1 (PDB
entry 1DVN). The RCL (red) acts as bait for proteases in the active form where it is solventexposed; it is inserted into central B-sheet A in the latent form. Several steps in the mechanism
of the transition to the latent form have been proposed, and it appears that local unfolding within
key regions is involved.30, 31 The shutter region (teal) expands, and the gate region loops (blue)
rearrange during the RCL insertion that occurs during the latency conversion. Helix F (purple)
may be displaced temporarily during unfolding of the hydrophobic core and/or rearrangement in
the bottom half of the shutter when the RCL is added as an additional strand in the central βsheet. The flexible joint region (green) is an important site for PAI-1 protein−protein
interactions, including binding of the SMB domain.22 The structure and location of histidines 2
and 3 are shown in orange for each view of the active or latent form of PAI-1.
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Interestingly, several parallels can be drawn when comparing disease states due to
dysregulation of PAI-1 to those due to copper homeostasis. Physiological copper concentrations
are under stringent temporal and spatial control within and outside cells. Copper is a required
cofactor for the function of many proteins, but in excess is highly toxic.34, 35 Copper is integral to
wound healing and angiogenesis, as its removal retards both processes.36 Copper is known to be
involved in vascular permeability, platelet-endothelial interactions, and the activation of smooth
muscle cells.37 On the other hand, elevated levels of copper can lead to oxidative damage
including double strand DNA breaks, lipid peroxidation, and protein oxidation. 34 Although
virtually all circulating copper is bound to proteins, namely ceruloplasmin or serum albumin, the
concentrations of copper(II) and PAI-1 within several biological compartments are such that
physiologically relevant interactions can impact PAI-1 function. 38-41
This study aims to determine the molecular basis for copper effects on PAI-1 stability and
overall function. Previous studies involving surface plasmon resonance with a nickel-NTA chip,
stopped flow binding measurements, and HDX-MS supported a specific metal ion binding site
within PAI-1.24, 29, 33 Several unanswered questions remain regarding copper effects on PAI-1:
Where do copper ion(s) bind to PAI-1? How does copper binding increase the rate of PAI-1
latency conversion? Alternatively, how does copper delay PAI-1 latency when bound to PAI-1 in
tandem with VN or the SMB domain? What is the affinity and stoichiometry of PAI-1-copper
interactions? To investigate these questions, we have targeted histidine residues using sitedirected mutagenesis and have compared copper binding and functional effects with wild-type
PAI- 1. We have utilized isothermal titration calorimetry (ITC) and gel-based assays to
characterize metal-binding properties. Furthermore, we have used activity measurements and
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rates of latency conversion to determine whether the targeted histidines coordinate copper at a
site that leads to the rapid loss of activity in PAI-1.
2.2
2.2.1

Materials and methods
Protein expression, purification and activity measurements
Wild-type PAI-1 and variants were cloned in a pET24d expression plasmid and expressed

in Rosetta 2 DE3 pLysS E. coli cells. PCR-based site directed mutagenesis was used to introduce
mutations to the triplet codons encoding for histidines 2 and 3 and tryptophan 175 of PAI-1 to
create H2A, H3A, H2AH3A, and H2AH3AW175F PAI-1 variants. Each of the mutations was
confirmed by DNA sequencing. Wild-type PAI-1 and variant constructs were transformed into
the expression cell line, grown, and expressed using established protocols.24 A standard three
step purification scheme was employed, but with some noTable adjustments for the variants, as
follows.24 Cell lysis, and the initial step of ion exchange chromatography were performed at pH
5.5 due to the change in pI when the N-terminal histidines were absent. This resulted in
improved binding to the sulfopropyl column, and improved separation within the elutions. Also,
the N-terminal histidines are required for wild-type PAI-1 binding to an immobilized metal
affinity chromatography column (IMAC). Since variants lacking the histidines failed to bind to
an IMAC column, we used hydrophobic interaction chromatography with separation on a Phenyl
Sepharose column instead. PAI-1 was dialyzed into 20 mM KH2PO4, 600 mM (NH4)2SO4, 1 mM
EDTA, pH 7 overnight, loaded onto the Phenyl Sepharose column, and eluted with a linear
reverse (NH4)2SO4 gradient (600 mM-10 mM). In the final step of the purification, the protein
was concentrated, and loaded on a size exclusion chromatography column as previously
described.24
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The activity of wild-type and variant forms of PAI-1 was measured using standard
assays.24 PAI-1 was mixed with tPA at varying molar ratios ranging from 0.25 to 4 (PAI-1:tPA).
The inhibitory capacity of PAI-1 was measured in a gel-based assay wherein the PAI-1:tPA
complex at each molar ratio was monitored and quantified by densitometry. PAI-1 inhibition of
proteases was also measured in a kinetic assay in which the tPA-substrate (Spectrozyme tPA,
Sekisui Diagnostics) was added to the PAI-1/tPA mixture. Cleavage of the p-nitroanaline group
of Spectrozyme tPA was detected by absorbance at 405 nm, allowing for measurement of tPA
activity over time at each molar ratio of PAI-1:tPA. Purified active wild-type PAI-1 fully inhibits
tPA with 1.25 molar equivalents of PAI-1. Latent PAI-1 was generated by dilution in buffer (50
mM sodium phosphate, 300 mM NaCl, 1 mM EDTA, pH 6.25) to a 5 μM concentration, and
incubation at 37 °C with light stirring for 6 days. The aforementioned activity measurements
were performed to confirm that no active PAI-1 remained in the mixture.
2.2.2

Metal ion titration gel assay
To determine the copper(II) concentrations required to induce accelerated PAI-1 latency,

we used a gel-based metal ion titration assay. Serial dilutions of copper(II) sulfate were prepared,
resulting in final copper(II) concentrations ranging from 5-1000 μM. Addition of copper(II)
resulted in a drop of as much as 0.2 pH units, so the solution was readjusted using NaOH.
Incubation with metal was initiated by adding PAI-1 at a final concentration of 4 μM and
maintaining the mixture at 37°C in 50 mM MOPS, 100 mM (NH4)2SO4 pH 7.4 for 30 minutes.
After the 30-minute incubation, PAI-1 was mixed in a 1:1 ratio with single chain tPA (Molecular
Innovations). Three control samples (PAI-1, tPA, and PAI-1/tPA) were also tested in which
copper(II) is not included. Non-reducing SDS-PAGE dye was added to each sample, followed by
boiling for 10 minutes prior to loading on the gel. The free/latent PAI-1, free tPA, and PAI-1/tPA
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complex in each sample were separated and visualized by SDS-PAGE electrophoresis in a 4-12
% gradient gel (Invitrogen). Samples were subjected to electrophoresis at 150 V for 75 minutes.
SDS-PAGE gels were stained with Coomassie blue dye overnight, followed by three destaining
steps of 90 minutes in deionized water containing 30 % methanol and 7.5 % glacial acetic acid.
Gel pictures were captured using a Chemidoc XRS molecular imager (Biorad), and gel band
densitometry of the PAI-1/tPA complex bands was performed using Imagelab (Biorad). The
band intensity of each sample was normalized to 100 % with an untreated PAI-1/tPA complex
sample, and to 0 % using the gel background. Averages and error were generated (n = 2) for each
assay, and the normalized band intensities were plotted as a function of the logarithm of total
copper(II) concentration. The midpoint copper(II) concentration for wild-type PAI-1 or each
variant was extrapolated from the semi-log plots as the copper(II) concentration at which 50 %
of PAI-1/tPA complex was observed; this measurement was used as an expression of relative
metal “sensitivity” of the various forms of PAI-1.
2.2.3

Stability kinetics assay
To measure the half-life of PAI-1 latency conversion, stability assays were performed.

PAI-1 at 0.1 μM was incubated in 50 mM MOPS, 100 mM (NH4)2SO4, 0.1 mM EDTA pH 7.4 at
37 °C. At specific time points, aliquots of PAI-1 were taken and mixed with 0.1 μM two-chain
tPA (Molecular Innovations), in 50 mM MOPS, 100 mM (NH4)2SO4, 2 mM EDTA, 1% bovine
serum albumin, pH 7.4. Individual samples were analyzed in 96-well plates by mixing with a
final concentration of 1 mM Spectrozyme tPA substrate (Sekisui Diagnostics). The reaction was
monitored over a 5-minute time period via tPA substrate cleavage at the p-nitroanaline group that
absorbs at 405 nm. This measurement was conducted in triplicate for multiple incubation times
that covered a range up to 10 times the PAI-1 half-life. The averages of the reaction slopes were
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entered into GraphPad Prism Software for analysis. The reaction slopes were plotted as a
function of PAI-1 incubation time to calculate tPA activity over time. Taking the negative slope
and normalizing the data (100 % at t = 0; 0 % at the lower baseline time points) yielded the
normalized PAI-1 activity as a function of PAI-1 incubation time. To determine the rate of
latency conversion (klat), the data were fit to the exponential decay equation xt = x0 e-kt, where xt
is the amount of active PAI-1 at a given time, x0 is the amount of PAI-1 at time 0, k is the rate of
latency conversion, and t is time. The half-life of latency conversion was determined as ln(2)/k.
For assays involving copper(II), PAI-1 was incubated in the same buffer with 215 μM copper(II)
sulfate added. The buffer was corrected for pH change due to copper(II) addition with NaOH.
For assays involving the SMB domain, a 1:2 PAI-1:/SMB complex was formed prior to
incubation at 37 °C or copper(II) addition.
2.2.4

Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was used to determine the thermodynamic

parameters associated with copper(II) interactions with PAI-1. Active and latent forms of wildtype and variants of PAI-1 were dialyzed into 100 mM MOPS, 250 mM (NH4)2SO4 at 10 °C for
two hours. Because of the relative instability of the H2AH3A variant of PAI-1, our studies on
H2AH3A PAI-1 utilized a variant that contained an additional mutation, W175F. The W175F
switch is a well characterized substitution used to stabilize the active form of PAI-1 during
purification and to ensure that a significant amount of latent H2AH3A PAI-1 did not accumulate
during the ITC experiment.42 Residue 175 is not proximal to the N-terminus and is not involved
in metal ion coordination or its subsequent effects on PAI-1 stability. Copper(II) solutions were
prepared by diluting a copper(II) sulfate into the matched dialysate buffer. The copper(II) stock
concentration was verified using atomic absorbance spectroscopy, and the pH corrected to 7.4 at
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10 °C using NaOH. Twenty micomolar PAI-1 (2.2 mL total volume) and copper(II) solution (4
mL) were degassed under vacuum for 10 minutes at 5 °C prior to loading into the (Malvern)
MicroCal VP-ITC. The PAI-1 solution was loaded into the ITC cell (1.394 mL), and the
copper(II) solution was loaded into the ITC syringe. The reference and experimental ITC cells
were equilibrated to 10 °C prior to the start of the experiment. After a preliminary injection of 2
μL, each additional injection consisted of a 4 μL injection at 120 or 240 second intervals.
Experiments were performed at least in duplicate. Control experiments measuring dilution heats
were performed in which the copper(II) solution was injected into buffer. The data were baseline
corrected using NITPIC software (University of Texas, Southwestern), and fit to either a singlesite or two-site non-symmetric binding model in SEDPHAT (National Institutes of Health). The
data and fits were represented using GUSSI software (University of Texas, Southwestern).
2.3
2.3.1

Results
PAI-1 variants exhibit altered metal sensitivities
The N-terminus of PAI-1 comprises a consensus copper binding motif similar to sites that

have been characterized in serum albumin, superoxide dismutase, and prion protein (PrPc).43-47
This motif contains two histidines, H2 and H3, which are thought to be involved in binding Cu 2+.
To test for differences in copper binding, we generated three variants in which the N-terminal
histidines were replaced with alanine residues, denoted as H2A, H3A, and H2AH3A PAI-1. This
notion proved true and required changes in our protein purification protocols. Whereas wild-type
PAI-1 can be purified using an immobilized metal affinity column, variants lacking these
histidines did not bind to a nickel-charged metal affinity column, providing direct evidence that
these residues are assessable and can coordinate metal ions. 24
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While this result clearly establishes that a metal-binding site exists near the N-terminus of
PAI-1, the key question is to determine whether copper binding effects the transition between
active and latent forms of PAI-1. Initially, a gel-based copper sensitivity titration assay was
developed to determine the copper(II) concentrations that invoke an accelerated rate of latency
conversion on PAI-1. For this assay, PAI-1 samples were incubated with Cu2+ concentrations of
5 - 1000 μM for 30 minutes, and then mixed with tPA. The samples were separated by nonreducing SDS-PAGE. After staining, the band intensities of the PAI-1/tPA complex at each
copper(II) concentration were quantified using gel densitometry. At low concentrations of Cu2+,
PAI-1 exhibits robust complex formation with tPA, indicating that it remains in an active form
(Figure 2.2a). At intermediate copper(II) concentrations, there is clearly a mixture of inactive
PAI-1 and the PAI-1/tPA complex, and at high metal concentrations, all PAI-1 is latent and no
PAI-1/tPA complex is observed. The data yield a sigmoidal curve in a semi-log plot, in which
the midpoint of the transition represents the effective concentration of copper(II) that accelerates
the latency transition (Figure 2.2b). The midpoint in the curve for wild-type PAI-1 is ~150 μM
Cu2+ and serves as a benchmark “sensitivity” for comparison to variants lacking the
hypothesized copper binding residues (Table 2.1). It should be noted that these titrations are not
equilibrium measurements because they capture points across a time-course for the latency
conversion for a mixture of free PAI-1 and the PAI-1-copper complex. The copper(II)-PAI-1
complexes have different half-lives for the latency transition, so that the wild-type and variant
forms of PAI-1 can be reliably compared with this method only when the t1/2 values for latency
of the copper-bound and -free species are similar for the wild-type and engineered forms of PAI1.24
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Figure 2.2

Copper(II) Titration Gel Assay for wild-type PAI-1

a) Equimolar mixtures of PAI-1 and tPA were prepared after 30 minute incubations of PAI1 with copper(II) at a wide range of concentrations (5-1000 μM, total). Lane 1 contains a
molecular ladder, Lanes 2-4 are controls in which PAI-1, tPA, and PAI-1/tPA,
respectively, were incubated without copper(II). Each subsequent lane contains PAI1/tPA mixtures incubated with varying copper(II) concentrations, as indicated.
Densitometry of the PAI-1/tPA complex (series of bands above the 100 kDa band) within
the gel was quantified using ImageLab. PAI-1 incubated without copper(II) (lane 3) and
gel background (0 %) were used to normalize each data point as a percentage.
b) The percent of PAI-1/tPA complex formation is plotted as a function of the total
copper(II) concentration. The metric for comparison of wild-type PAI-1 to PAI-1 variants
is taken as the midpoint in copper(II) concentration (“sensitivity”) for which 50 % PAI1/tPA complex is observed in the densitometry data.
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A variant targeting the copper binding domain would exhibit decreased sensitivity
compared with wild-type PAI-1, and would require higher copper(II) concentrations to accelerate
PAI-1 latency. Thus, if copper(II) coordination by the histidine residues accounts for the
accelerated rate of PAI-1 latency, then we predict that the copper(II) sensitivity of these variants
would be decreased. In contrast, we observed the opposite effect, in which variants lacking the
N-terminal histidines are more sensitive to copper(II) compared with wild-type PAI-1 (Figure
2.3). Each of the single variants (H2A, H3A) as well as the double variant (H2AH3A) of PAI-1
required lower copper(II) concentrations to induce latency, with midpoints in the sensitivity
curves of ~ 20 μM copper(II) (Table 2.1). This unusual observation indicates that the accelerated
latency of PAI-1 in the presence of copper(II) is not due to binding to the N-terminal histidines.
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Table 2.1

Copper Sensitivities of Wild-type and Variant Forms of PAI-1 Determined from
Gel Titration
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2.3.2

SMB domain binding dampens copper sensitivity of PAI-1
The SMB domain of VN binds within the flexible joints region of PAI-1, resulting in a

modest stabilization of the active form.21, 24 Using the gel-based copper titration assay, we tested
for the effect of SMB binding to PAI-1 on the copper sensitivity range for accelerated latency.
We expected that the formation of the PAI-1/SMB complex would lead to decreased copper
sensitivity, based on the stabilizing effects of SMB binding in the absence of copper(II) ions.
Wild-type PAI-1 combined with the SMB domain was indeed less sensitive to copper(II),
demonstrated by a midpoint in the gel titration assay of ~200 μM copper(II) (Figure 2.4a, Table
2.1). For comparison, we also tested H2AH3A PAI-1 combined with the SMB domain, and
observed a similar copper sensitivity. While these results represent a modest decrease in copper
sensitivity for wild-type PAI-1, they reveal a much more significant decrease for H2AH3A PAI1. Since binding of the SMB domain alters latency kinetics independent of copper(II) effects,
comparisons with these data alone are to be taken with caution in this non-equilibrium assay.
Nonetheless, it is clear that binding of the SMB domain to both wild-type PAI-1 and the
H2AH3A variant dampens sensitivity to copper so that differences in the rate of the latency
transition that arise due to the histidine replacements are not observed. Also, incubating PAI-1
and copper(II) in a higher ionic strength (250 mM (NH4)2SO4 compared with the normal assay
concentration (100 mM (NH4)2SO4) rendered both wild-type PAI-1 and the double histidine
variant almost completely insensitive to copper(II), so that latent PAI-1 did not form to any
appreciable extent in the gel assay (Figure 2.4b).
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Figure 2.3

Copper titration comparing wild-type PAI-1 versus H2AH3A PAI-1.

Equimolar mixtures of PAI-1 and tPA were prepared after 30 minute incubations of PAI-1 with
varying copper(II) concentrations (10-1000 μM, total) in 50 mM MOPS, 100 mM (NH4)2SO4 pH
7.4 at 37 °C. Gel densitometry of the PAI-1/tPA complex was quantified using ImageLab. PAI-1
incubated without copper(II) and gel background (0 %) were used to normalize each data point
as a percentage. The percent of PAI-1/tPA complex formation is plotted as a function of the total
copper(II) concentration. Wild-type and H2AH3A PAI-1 are represented by inverted triangles
and circles, respectively.Copper stabilizes the PAI-1/SMB complex through binding to the Nterminal site
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2.3.3

Copper stabilizes the PAI-1/SMB complex through binding to the N-terminal site
To determine how the binding of copper(II) to N-terminal histidines affects the rate of

PAI-1 latency, we measured the latency conversion kinetics of these variants in the presence and
absence of copper(II) and the SMB domain (Figure 2.5, Table 2.2). We first reproduced our
previous studies on wild-type PAI-1, but instead used a MOPS buffer system, which offers the
benefit of decreased copper(II)-buffer interaction compared with Tris buffer used previously.24
Wild-type PAI-1 remains in the active form for a half-life of ~70 minutes in the MOPS buffer.
Ligand binding in MOPS buffer imparts the same effects on PAI-1 as in Tris buffer; thus wildtype PAI-1 in the presence of copper(II) (215 μM) undergoes latency significantly faster, with a
half-life of ~20 minutes. As observed previously, wild-type PAI-1 is modestly stabilized by
incubation with the SMB domain of VN, with a half-life for the latency conversion of ~125
minutes. In the presence of copper(II) and the SMB domain, PAI-1 is further stabilized, with a
half-life of ~170 minutes.
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Figure 2.4

Effects of copper and/or SMB binding on stability kinetics measurements of wildtype and H2AH3A PAI-1

Wild-type and H2AH3A PAI-1 were incubated at 0.1 μM in 50 mM MOPS, 100 mM
(NH4)2SO4, 0.1 mM EDTA, pH 7.4 at 37 °C. Four conditions were tested: PAI-1 alone (white
bars), PAI-1 + 215 μM copper(II) (black bars), PAI-1 + SMB domain (gray bars), and PAI-1 +
SMB domain + copper(II) (checkered bars). At various time points, PAI-1 is mixed with 0.11
μM tPA to react with all PAI-1 remaining in the active form. tPA activity is measured by
addition of 1mM (final) Spectrozyme tPA substrate and the absorbance of substrate cleavage is
monitored at A405 for 5 minutes. PAI-1 inhibitory activity is plotted versus incubation time and
fit to an exponential decay function to determine the rate of latency transition.

62

Table 2.2

Kinetic properties for copper binding to wild-type and H2AH3A PAI-1
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Next, we tested the H2AH3A PAI-1 variant under the same conditions to assess the role
of copper binding to these residues in the PAI-1 latency conversion (Figure 2.5, Table 2.2). We
measured the rate of latency of the H2AH3A variant alone to determine how the N-terminal
histidine substitutions themselves influence the latency transition independent of copper(II)
effects. In these assays, H2AH3A PAI-1 has a half-life of latency conversion of ~74 minutes,
which is not statistically different from wild-type PAI-1, indicating that the introduction of these
amino acid substitutions has no intrinsic effect on the rate of the latency transition in PAI-1.
Also, H2AH3A PAI-1 is destabilized in the presence of copper(II), with a half-life for the
latency conversion of 6 minutes, a shorter half-life than observed with wild-type PAI-1 bound to
copper(II). This more pronounced rate of acceleration induced by copper binding to the variant
compared to wild-type PAI-1 agrees well with the increased copper(II) sensitivity of the
H2AH3A variant observed in the gel titration assay. This result clearly indicates that a second
metal binding site remains in the H2AH3A variant of PAI-1 and suggests that this additional site
is responsible for the accelerated latency conversion. Furthermore, since the half-life for the
latency transition is actually shorter with the H2AH3A PAI-1 variant, the increased latency
differential for this variant relative to wild-type PAI-1 points to a potential stabilizing role of
Cu2+ binding to the N-terminal histidines.
Based on results from the gel titration assay (Figure 2.4a), we hypothesized that
copper(II) binding to the N-terminal histidines is the source of the enhanced stabilization
observed when copper(II) is incubated with the PAI-1/SMB complex. Whereas the copper
titration gel assay with the H2AH3A PAI-1 variant indicated that metal binding to these two
histidines was not the interaction that promotes that latency conversion, the assay with the
H2AH3A PAI-1/SMB complex in fact revealed a pronounced stabilization equivalent to that
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seen with the wild-type PAI-1/SMB complex. Consistently, latency conversion kinetics indicated
that H2AH3A PAI-1 bound to SMB domain is stabilized to the same extent as wild-type PAI-1,
with a half-life of latency conversion of ~ 125 minutes (Figure 2.5, Table 2.2). Interestingly
however, the H2AH3A PAI-1/SMB complex was not further stabilized compared to wild-type
PAI-1 by the binding of copper, with a half-life of latency conversion of only 89 minutes. This
result stands in contrast to observations of the wild-type PAI-1/SMB complex behavior and
supports our hypothesis, indicating that the enhanced stabilization of the PAI-1/SMB complex is
imparted through copper(II) binding to the N-terminal histidines of PAI-1. Thus, one of the most
unusual and striking features we observed in our metal studies with PAI-1, i.e. that copper
binding concurrently with the SMB domain yields a highly stable form of PAI-1 that converts to
latency more slowly than with the SMB domain alone, can be attributed to metal coordination by
these N-terminal histidines.24, 29, 33
2.3.4

ITC identifies differences in Cu(II) interactions with active, latent and variant
forms of PAI-1
Isothermal titration calorimetry (ITC) proved to be an important tool for investigating the

thermodynamic characteristics of copper(II) binding to PAI-1. This method offers the advantage
of providing a full thermodynamic characterization for the interaction, with affinity and
stoichiometry explicitly determined, along with binding enthalpies. In the ITC experiments,
copper was titrated from a stock solution via small injections into a thermal cell containing PAI1, and the power needed to maintain the sample’s temperature was measured. In order to
maintain the active form of PAI-1 over the time course of the experiment, we lowered the
experimental temperature to 10 °C, and increased the (NH4)2SO4 concentration to 250 mM. The
increased (NH4)2SO4 protects against non-specific metal ion effects, and was shown in the gel
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titration assays (Figure 2.4b) to render PAI-1 relatively insensitive to metal effects on the latency
transition. It should be noted that the PAI-1 latency transition itself results in no observable heat
changes in control ITC experiments.48
Titrations of active wild-type PAI-1 with copper(II) ranging up to 650-800 μM were
performed and the data were subject to global fitting analysis. We observed one sharp transition
with an n-value of 1.2 in all cases, so the data were fit to a single-site binding model. Fitting of
replicate data yielded an average Kobs value of 5.4 x 107 and ΔHobs = -16.2 kcal/mol (Figure 2.6,
Figure A.1, Table 2.3). This corresponds to an effective Kd = 19 nM, where the Kd = 1/Kobs, and
averages for ΔGobs and -TΔSobs equal to -10.0 and 5.9 kcal/mol, respectively. These results agree
well with prior analyses of PAI-1-copper(II) binding using stopped-flow kinetics that also
determined the interaction affinity (Kd = 90 nM),33 and give evidence that copper(II) binding to
the active WT PAI-1 complex is driven by a highly favorable change in enthalpy with a slightly
unfavorable change in entropy penalty. By contrast, latent wild-type PAI-1 binds copper(II) with
two distinct binding transitions, one tight binding transition accompanied by a significantly
weaker one. Global fits to multiple data sets indicated that latent PAI-1 binding of copper(II) fits
best to a two site non-symmetric binding model, yielding average Kobs terms of 2.4 x 107 and 3.4
x 104 , and ΔHobs terms of –12.0 and -11.2 kcal/mol for the high and low affinity binding sites,
respectively (Figure 2.7, Figure A.2, Table 2.3). These parameters correspond to average Kd
values of 42 nM and 30) μM for the high and low affinity sites, respectively. The high affinity
copper(II) binding event in latent WT PAI-1 shows similar free energy to that in the active PAI-1
described above, although the enthalpic and entropic contributions are different compared with
the site in the active form. Interestingly, the weaker binding site has a similar ΔH obs term to the
high affinity site, yet it’s –TΔSobs term is more destabilizing, which effectively weakens the
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copper(II) binding affinity to this site (Table 2.3). The observed thermodynamic parameters are a
good benchmark for comparison within this study, but further analysis and deconvolution of the
data from these complex ion equilibria are required to identify the origins of these changes.
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Figure 2.5

Isothermal titration calorimetry of active, latent and variant forms of PAI-1

A representative isotherm is shown for the titration of active wild-type PAI-1 with copper(II).
Isotherms for the full data set for copper titration into active wild-type PAI-1, including global
fitting with replicates of four concentrations of copper(II) titration solutions, are shown in Figure
1S. The data are baseline corrected in NITPIC software, and fit to a one-site binding model in
SEDPHAT software. The data and fit are represented in GUSSI software via heats of injection
(kcal/mol) as a function of copper(II)/PAI-1 molar ratio.
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Table 2.3

PAI-1
Variant

Active
WT
Active
WT
Active
WT
Active
WT

Thermodynamic properties for Cu(II) binding to wild-type and H2AH3A PAI-1 at
10°C
Mod
el (n)

[Cu2+]

Kobs, M-1

Kda

ΔGobsb
(kcal/mol)

1

650 M

1

700 M

1

750 M

1

800 M

7.6 (± 3.1)
x 108
8.2 (± 4.9)
x 107
4.8 (± 5.5)
x 107
4.1 (± 2.8)
x 107
2.2 (±

high affinity

0.4) x 107

13 (± 9)
nM
19 (± 10)
nM
20 (± 20)
nM
24 (± 12)
nM
46 (± 10)
nM

-10.2
(± 0.3)
-10.0
(± 0.7)
-9.9
(± 0.4)
-9.8
(± 0.2)
-9.5
(± 0.1)

low affinity

4.20 (±
2.8) x 104

24 (± 12)
μM

-6.0
(± 0.6)

2.6 (± 0.7)
x 107
2.9 (± 1.1)
x 104
4.2 (± 0.9)
x 104

38 (± 10)
nM
35 (± 12)
μM
24 (± 5)
μM

-9.6
(± 0.2)
-5.8
(± 0.4)
-6.0
(± 0.1)

650 M
Latent
WT

2

750 M

ΔHobs
(kcal/mol)

-TΔSobsc
kcal/mol)

-15.9 (± 0.3)

5.7 (± 0.3)

-16.4 (± 0.6)

6.3 (± 0.7)

-15.9 (± 1.2)

5.0 (± 1.2)

-16.4 (± 0.6)

6.5 (± 0.6)

-12.0 (± 2.8)

2.5 (± 0.1)

-11.2 (± 3.0)

5.1 (± 0.6)

-12.0 (± 2.9)

2.4 (± 0.2)

-11.2 (± 3.1)

5.4 (± 0.2)

-20.0 (± 12.0)d

14 (± 12)d

Latent
WT

2

Active
H2AH3A

1

1200 M

Active
H2AH3A

1

1350 M

2.7 (± 2.1)
x 104

37 (± 12)
μM

-5.7
(± 0.4)

-51.6 (± 13.0)d

46 (± 13)d

Latent
H2AH3A

1

1050 M

5.2 (± 4.0)
x 104

19 (± 15)
μM

-6.1
(± 0.6)

-37.5 (± 11.0)d

31 (± 11)d

Latent
H2AH3A

1

1200 M

7.7 (± 4.6)
x 104

13 (± 6)
μM

-6.3
(± 0.4)

-16.4 (± 0.6)d

10 (± 0.4)d

high affinity
low affinity

a Kd calculated from the following relationship: Kd = 1/Kobs
b ΔGobs calculcated from ΔGobs = -RT ln Kobs.
c –TΔSobs term calculated from ΔGobs = ΔHobs - TΔSobs
d Parameters measured at the low sensitivity limit of the ITC and likely have significant error
associated with them.
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For comparison, the PAI-1 variant housing the H2AH3A substitutions was also studied
via ITC. As anticipated, copper(II) titrations on active and latent forms of H2AH3A PAI-1
revealed significant differences compared to wild-type PAI-1 binding of copper(II) . Only a
single binding event was observed for both latent and active forms of this variant. Superficially,
this binding event resembles the weak second binding event observed in the latent wild-type
PAI-1. The thermodynamic parameters extracted from the Cu2+ binding isotherm of the active
H2AH3A PAI-1 were an average Kobs = 3.4 x 104 and ΔHobs value of -35.8 kcal/mol ( Figure 2.8,
Figure A.3, Table 2.3). This corresponds to an average Kd value of 30.5 μM. This value agrees
well with the gel assay result in which the PAI-1 “sensitivity” midpoint value for the latency
conversion was ~20 μM (Figure 2.3), which is similar to the affinity the weak binding site in the
latent WT protein. Although we have good faith in the accuracy of the Kobs and ΔGobs term from
this series of ITC experiments, the ΔHobs term reported here is likely inaccurate.49 The ΔHobs
term is primarily determined from the first injections of the experiment, and when the affinity of
this binding isotherm is low there is limited curvature in the isotherm, which leads to inaccuracy
in the measured enthalpy term. Additional experiments are required to assess the impact of the
ΔHobs for this system. The absence of the tight binding event within H2AH3A PAI-1 suggests
that the higher-affinity site can be attributed to the N-terminal histidines of PAI-1. The latent
H2AH3A PAI-1 exhibits similar copper(II) binding compared to the active H2AH3A variant.
Latent H2AH3A PAI-1 binds copper(II) with a single binding event, with an average Kobs = 6.4
x 104 and ΔHobs value of -27.0 kcal/mol (Figure 2.9, Figure A.4, Table 2.3). Similar to the active
variant described above, the ΔHobs term for the latent H2AH3A PAI-1 is likely inaccurate. At
this level of analysis, we consider the copper(II) binding events to active and latent H2AH3A
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PAI-1 to be indistinguishable, where they both yield weak binding events with highly similar
binding constants.
2.4
2.4.1

Discussion
Connecting copper binding to PAI-1 and its functional stability as an active
inhibitor
Hydrogen deuterium exchange measurements showed that copper(II) binding to PAI-1

increases protein dynamics in regions relevant to the latency process.29 PAI-1 lacking the Nterminal histidines retains the copper(II) effects on protein dynamics, which are localized to the
same regions as in wild-type PAI-1.29 This is further evidence that copper binding to the Nterminal domain cannot be solely responsible for the accelerated latency transition, and that the
other metal-binding site in PAI-1 may be involved in this process.
The goal of this study was to explore the effects that copper(II) invokes on the stability of
active PAI-1 as observed previously in the metal-dependence in rates of the latency conversion
and changes in dynamics.24, 29, 33 The data collected for the H2AH3A variant of PAI-1 identified
the histidine-rich, N-terminal region of PAI-1 to be involved in copper(II) binding. A
comparison of the properties of wild-type PAI-1 and the H2AH3A variant (summarized in
Tables 2.1, 2.2, and 2.3) establish that H2AH3A PAI-1 is more sensitive to latency conversion,
and indeed converts faster in the presence of saturating levels of copper(II) compared with wildtype PAI-1. Our ITC results demonstrate that there is a single, high-affinity copper(II) binding
site in active PAI-1 (Kd ~ 40 nM), whereas there are two copper-binding sites in latent PAI-1
(Kd values were measured to be 40 nM and 40 μM). Substitutions for the N-terminal histidines
perturbed the high affinity copper(II) binding site in active PAI-1, and this variant protein had an
accelerated rate of latency.
71

Combining these results, we predict the low affinity copper(II) binding site promotes
conversion to the latent form of PAI-1 and the high affinity, N-terminal copper(II) binding
domain of PAI-1 plays a role in chelating free copper(II) in solution, effectively protecting the
active form of the protein. Upon conversion from the active to the latent form, major structural
changes occur in PAI-1, where two distinctive metal-binding sites are present. Structural
differences in the latent form involve the insertion of the RCL into the central β-sheet, which
displaces helices D and E in the flexible joint region and moves them away from the N-terminus
(Figure 2.1). Based on the heat of copper(II) coordination, it is likely that the latent form of PAI1 contains different copper(II)-coordinating ligands to complement the N-terminal histidines
and/or to comprise the second weaker site. In H2AH3A PAI-1, there is no high affinity site to
bind adventitious copper(II), which then leads this variant to sampling conformations more
similar to the latent form which are ultimately highly sensitive to copper(II). These differences
affect the results collected for wild-type and variant forms of PAI-1 in the gel assays. Another
possibility is that the high salt conditions used for the ITC experiments may disrupt copper(II)
binding to the weaker metal-binding site in the active protein. This notion is supported by the gel
assays at matching salt concentrations, in which the stability of wild-type or H2AH3A PAI-1
was desensitized to copper(II) over a broad concentration range (10 μM to > 1000 μM). While
specific disruption of the weaker metal-binding site is conceivable, the effect of higher
ammonium sulfate could also be a more general effect, consistent with the known effects of
ammonium sulfate solutions on protein stabilization.
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2.4.2

Copper coordination by the N-terminal histidines stabilizes the PAI-1/SMB
complex
We have reported previously that wild-type PAI-1 in complex with the SMB domain of

VN is further stabilized by copper(II) binding; however H2AH3A PAI-1 does not exhibit the
synergistic effects of copper(II) and SMB binding.24 Thus, it appears that copper(II) binding to
the N-terminal histidines is responsible for the stabilizing effect of metal in combination with
PAI-1 binding by the SMB domain. The stabilizing effects on PAI-1 that result from binding of
the SMB domain alone are attributed to binding in the flexible joints region, resulting in
widespread restriction of dynamics, especially in nearby helices D, E, and F. 28 Copper binding to
the PAI-1/SMB complex results in a restriction of dynamics near the N-terminus of PAI-1, a
phenomenon that does not occur in the absence of SMB domain.29 This restriction of dynamics
likely influences a local unfolding event on the proximal hA that occurs on a time scale relevant
to the latency conversion process.30
2.5

Conclusions
Copper binds to the N-terminal histidines of PAI-1 (H2, H3), but binding to this site does

not result in accelerated latency in the presence of copper. In fact, binding of copper(II) to this
site stabilizes the active form of PAI-1. We propose that a second, low-affinity copper(II)
binding site is responsible for the copper(II)-related destabilization of PAI-1. While this second
site remains to be identified, it appears that the different structures of active and latent PAI-1
allow for alternative copper(II) coordination sites. Potential Cu2+ binding residues near the Nterminal histidines in active PAI-1, including E81 and H364, will be a focal point of future
studies. Whether or not the weaker, destabilizing copper(II)-coordination site represents an
alternative binding mode in active PAI-1 or a distinct, independent site also must be a focal point
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of future studies. While the N-terminal histidines do not constitute the binding site that promotes
the latency transition, this site is valuable in mediating the striking synergistic effects between
copper(II) binding and the SMB domain. Interestingly histidine-rich, N-terminal copper(II) and
nickel(II) binding domains have been recently identified in numerous proteins, but a specific role
for these metal-binding motifs is unclear.50-53 It is clear, however, that this N-terminal site in
PAI-1 is critical because it appears to stabilize the active conformation of PAI-1 with SMB
present when metal ions would otherwise quickly render PAI-1 in its latent form, which is
ineffective as an inhibitor.
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CHAPTER III
IMPACT OF THERMAL STABILITY OF PROTEINS UPON CUPRIC ION BINDING:
A CASE STUDY OF COPPER(II) BINDING TO HUMAN
CARBONIC ANHYDRASE II
3.1

Introduction
Carbonic anhydrases (CAs) are a class of well-studied and ubiquitous metalloenzymes

that catalyze the reversible hydroxylation of CO2 to HCO3-.1 CA is a Zn-containing monomeric
metalloenzyme with a molecular weight of ∼29 kDa (Figure 3.1). In Type 2 CAs, including
human CA II (CA), the zinc(II) ion is coordinated in a pseudotetrahedral coordination mode by
three histidine side-chain residues (His94, His96 and His119) leaving one labile coordination
site, which is generally occupied by a nucleophilic water/hydroxide ion. 1-5 CA turns over at
nearly the rate of diffusion, where it is one of the fastest enzymes characterized thus far with
a kcat of 1.4×106 s−1. The hydrolysis of CO2 catalyzed by CA is defined by two half reactions that
follow a classical ping-pong type mechanism2, 6 In the first half reaction, CO2 diffuses into the
active site, disrupting hydrogen bonding networks present in the active site pocket. Then the
zinc-bound hydroxide performs a nucleophilic attack on CO2 forming the bicarbonate ion
(HCO3-.) HCO3- is then released from the active site, where a solvent water molecule binds to
the zinc(II) ion regenerating the resting enzyme’s active site. The second half reaction is
hallmarked by a deprotonation of this bound water molecule to reform the zinc-bound hydroxide
ion, which readies the enzyme for successive rounds of catalysis. 2, 4, 5, 7-10
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Figure 3.1

Zn-CA active site

A) Figure created in Pymol (pdb 1CA2).
B) Zn-CA active is illustrated, showing 3 histidine residues (His94, His96 and His119) and one
water/hydroxide ion coordinating in a pseudotetrahedral coordination mode.
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Previously it has been shown that the zinc(II) ion can be readily removed from CA using
the Zn2+ chelator, pyridine-2,6-dicarboxylic acid (DPA), to generate a reasonably stable, metalfree form of CA. 11, 12 This apo-CA can be reconstituted with zinc(II) to yield a fully activated
holo-form of CA.13 Alternatively, apo-CA can be reconstituted with other transition metal ions,
including biologically available metal ions like Cu2+ 14-24and other non-biological metal ions.14, 15,
21, 23, 25

The general stability of the apo-, holo-, and remetallated-forms of CA makes this an

excellent model system to study the role metal ions play in stabilizing proteins using wellestablished biophysical methods.
Interestingly, CA has an additional N-terminal copper(II) binding site approximately 14
Å from the active site.26 This secondary binding site has been shown to have a higher affinity for
Cu2+ than the active site, and adopts a 4-5 coordinate N-terminal binding site that is consistent
with the copper(II)-ATCUN and copper(II)-ATCUN-like structures.16, 27-30 The two copper(II)
binding sites have been shown to be thermodynamically distinguishable, where the N-terminal
copper(II) binding site (CuA) and the active site (CuB) have experimentally determined ΔG and
ΔH values of -8.1 and -11.3 kcal/mol and -8.0 and -7.1 kcal/mol, respectively.16, 17 However, the
underlying dynamic processes that lead to these terms are still unclear, where transition metal ion
binding impacts protein stability beyond just forming new coordinate covalent bonds. Here,
temperature dependent copper(II) and zinc(II) binding studies are performed to elucidate the
impact of metal-binding induced conformational entropy changes. Through this effort, a higher
understanding of how metal ions shape the global stability of CA can be illustrated.
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3.2
3.2.1

Materials and methods
Sample preparation
The plasmid encoding human carbonic anhydrase II (pACA) was transformed into E. coli

BL21(DE3) cells (Agilent Technologies, Santa Clara, CA, USA). All E. coli cultures containing
this plasmid were grown with shaking at 37 °C in LB media containing 100 mg/L ampicillin. At
an approximate OD600 of 0.6, cultures were induced with 100 mg/L IPTG and allowed to grow
for another 4 hours. The cells were collected via centrifugation (6,000 rcf for 30 minutes) and
lysed by sonication (power level 5, 20% duty cycle for 6 minutes in a Branson Sonifier 450) in
50 mM Tris buffer (pH 7.4). Streptomycin sulfate was added to the cell lysate to a final
concentration of 1% (w/v) to precipitate DNA and was allowed to stir at 4°C overnight. Cell
lystate was clarified by centrifugation (50,000 rcf for 45 minutes) and then loaded onto a strong
anion exchange column (GE life sciences, HiTrap Q FF). Flow-through fractions containing the
protein of interest were collected and the column was regenerated with a 500 mM NaCl wash.
CA concentrations were determined by UV absorption at 280 nm (ε280 = 54,000 M−1 cm−1).
Protein activity was assessed using para-nitrophenyl acetate (pNPA) hydrolysis assays and were
performed as previously described.31, 32 All assays were performed in the final dialysis buffer at
pH 7.4. A 20 μL sample of 20 mM pNPA/acetonitrile was added to 1 mL of buffer in a
disposable cuvette. Up to 20 μL of a protein solution was then mixed into the cuvette and the
absorption at 404 nm was monitored for 60 seconds. Activity was calculated based on the
conversion of pNPA to p-nitrophenol (ε404 = 17,300 M−1cm−1). Fractions showing good activity
were concentrated via an ultrafiltration centrifugal device with a polyethersulfone (PES)
membrane with a 10K MWCO. The concentrated fractions were then loaded onto a Sephacryl S200 size exclusion column (GE Healthcare), which was subjected to an isocratic flow of 50 mM
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Tris buffer (pH 7.4) with 200 mM sodium chloride. Fractions showing good activity and
displaying a single band on an SDS-page gel were deemed to be pure CA. To ensure uniformity
in metal binding, metals present during the growth and purification steps were then chelated
from CA. Purified CA was dialyzed overnight against 1 L of 50 mM Tris buffer containing 50
mM dipicolinic acid (pH 7.4) as described previously to generate apoCA. 17, 26, 31 The purified CA
was then dialyzed against 2 L of 50 mM Tris buffer (pH 7.4) to remove the DPA and finally
dialyzed overnight against 1 L 100 mM TES buffer (pH 7.4). All experiments were performed in
this final dialysis buffer.
3.2.2

Isothermal Titration Calorimetry (ITC)
ITC experiments were carried out at 15 °C, 20 °C , 25 °C, 30 °C and 35 °C, using a

MicroCal VP-ITC calorimeter. Samples were buffered at pH 7.4 with 100 mM TES. A typical
experiment consisted of 70 μM apoCA titrated with 2 mM ZnCl2 or CuCl2 in matched buffers.
All solutions were degassed under vacuum prior to running the experiments. The ITC data were
fit as previously described.17, 26, 31 Data sets were collected in triplicate (or more) and the average
and standard error of the mean were reported for fitting parameters. All ITC data shown are the
baseline-corrected raw data, along with the integrated, concentration-normalized heat of reaction
(∆𝐻) versus the molar ratio of metal ion to protein (n). The free energy change term for the
experimental data was calculated for each experiment using the equilibrium constant obtained
from the best fit (𝐾). Experimental thermodynamic values obtained through ITC are a
combination of many different species in equilibria. To determine more accurate thermodynamic
terms for metal binding, the ITC data was deconvoluted, as described previously, into buffer
ionization heats, buffer-metal interaction heats, and protein binding heats.17 All reported values
have been corrected to reflect the metal-protein interaction alone.
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3.2.3

Circular Dichroism (CD)
Apo-, Zn-, CuZn- and CuCu-CA samples were all prepared by addition of a molar

equivalent of each metal to 1 μM apo-CA. For example, for the CuZn-CA sample, one
equivalent of ZnCl2 was first added to the protein and allowed to equilibrate for 30 min, and then
one equivalent of CuCl2 was added and again was allowed to equilibrate for 30 min. The final
concentrations in this sample are 1 μM each of CA, ZnCl2 and CuCl2. For the CuCu-CA, two
equivalents of CuCl2 were added to CA and allowed to equilibrate for 30 min. CD studies were
conducted using an Olis DSM 20 CD in a 1 mm pathlength quartz cell at 25°C. CD Spectra were
buffer corrected and the high volts were monitored and never exceeded 900 V, even at far-UV
wavelengths. The spectra were then corrected for concentration and data are shown as molar
ellipticity.
3.2.4

Denaturation Studies
Guanidine HCl (GdnHCl) denaturation studies were performed to further probe the

stability of each of the four forms of CA; apo-CA, Zn-CA, CuZn-CA and CuCu-CA. All
fluorescence data were measured by a Horiba FluoroMax 4 spectrofluorometer with a Quantum
Peltier-based heated/cooled cuvette holder and Microlab dual syringe auto-titrator (λex= 280nm,
λem=300-400 nm). A Starna Cells 1 cm path length quartz cuvette with a small magnetic stir bar
was used for mixing. Reported spectra are the average of a series of 5 scans made at 1-nm
intervals, 0.1 second signal integration time, and 5.0-nm entrance and exit slit bandpass, which
have been corrected relative to an appropriate baseline scan including the buffer and denaturant.
Protein concentrations were 0.05 μM in 100 mm TES buffer at a pH of 7.4, and the titrant
consisted of approximately 6.0-7.0 M GdnHCl. GdnHCl concentrations were determined as
previously described via an Abbe refractometer.33 The auto-titrator was loaded with 5 ml of
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GdnHCl and programmed for titration steps starting at 0.1 M and ending at 4.0 M GdnHCl.
Between titration steps, the sample was equilibrated with mixing for 300 seconds before each
spectrum was recorded. Unfolding curves were generated and fit to a two-state unfolding model
used to estimate the apparent unfolding Δ𝐺 𝑜 (𝐻2 𝑂) for each CA sample.34 Experiments were
repeated in triplicate and reported as the average, plus or minus the standard error of the mean.
3.3

Results

3.3.1

ITC of Zn2+ and Cu2+ binding at different temperatures show N-terminal Cu2+
binding to be enthalpically driven
Zn2+ and Cu2+ binding to apo-CA have been previously reported by the Emerson group.17,

26, 31

Titration of Zn2+ and/or Cu2+ into apo-CA yields a summation of enthalpic contributions for

multiple interactions and deconvolution of the binding data has allowed for a more accurate
determination of specific individual thermodynamic values associated with the equilibria of
metal binding to apoCA.17 All thermodynamic values presented here are pH and buffer
independent values obtained through the subtraction of reactions enthalpies for buffer-buffer and
metal-buffer interactions from the experimentally measured enthalpy of reaction. A
representative isotherm for the Zn2+ binding to apo-CA is shown in Figure 3.2. The raw injection
heats are shown in panel A, and the integrated change in enthalpy (ΔH) with the non-linear
regression fit are shown in panel B.
In order to probe the possible temperature dependence of binding, similar experiments
were conducted at four additional temperatures (15°C, 20°C, 30°C, and 35°C) and the corrected
thermodynamic values are shown in Table 1. The ΔG and –TΔS terms were calculated via
equation 3.1 and 3.2.
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(3.1)

(3.2)

Zn2+ binding to apo-CA yields a thermogram that can be fit to a single two-site binding
model, with a stoichiometry of 1, a ΔH of -14.7 ± 0.7 kcal/mol and a binding constant of
~3.6x10-9 at 25°C. The binding of Zn2+ is seen to be enthalpically driven, with the lower
experimental temperature of 15°C and 20°C indicating a drop in enthalpy of binding to -13.2 ±
0.3 kcal/mol and -12.0 ± 0.4 kcal/mol, respectively.
Cu2+ binding to apo-CA yields two distinctive two-site binding events, as previously
reported.17, 26 A high-affinity (CuA) site (~3.6x10-8 at 25 °C) is located at the N-terminus and a
secondary (CuB) site (3.3x10-5 at 25 °C) at the active site. The difference between the binding
constants has previously been reported to be 1000-fold at 25 °C, and those results agree with the
data reported here.17 For the CuA high-affinity site, temperature dependent studies show binding
to be entropically driven, with a ΔS term that is more negative in value as temperature is reduced,
indicating a reduction in overall structure upon binding. At higher temperatures, the ΔS term
becomes less negative, indicating that at these temperatures these is less reduction in protein
structure as metal ion binding occurs. Conversely, the Cu2+ binding to the active site (CuB)
shows a similar trend to the Zn2+ binding event to the active site, which is enthalpically driven.
The lower temperatures (15 °C and 20 °C) reflect lower enthalpy of binding, -6.1 ± 0.3 kcal/mol
and -7.1 ± 0.4 kcal/mol, and higher temperatures (30 °C and 35 °C) reflect higher enthalpy of
binding, -9.9 ± 0.5 kcal/mol and -11.1 ± 0.5 kcal/mol.

87

Table 3.1

pH and buffer independent thermodynamic values obtained through ITC
experiments at 298 K
Ka

ΔG
(kcal/mol)

ΔH
(kcal/mol)

-TΔS
(kcal/mol K)

Zn2+

Protein
Binding
Site
Apo-CA

3.6(±1.0)x109

-13.0 ±0.7

-14.7 ± 0.7

1.7 ± 0.3

Cu2+

Zn-CA

2.4(±0.9)107

-11.4 ±0.4

-9.8 ± 0.6

-1.6 ± 0.6

Cu2+

Apo-CA

3.3(±0.7)105

-7.5 ±0.6

-9.0 ± 0.5

1.5 ± 0.4

Cu2+

Cu-CA

3.6(±0.4)108

-11.7 ±0.4

-9.7 ± 0.6

-2.0 ± 0.6

Titrant
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To further investigate these seemingly entropy-linked binding events, we employed
conformational entropy methods to calculate the number of residues that fold upon metal ion
binding (ℜ𝑡ℎ ).35 Changes in heat capacity were determined from the slope of a plot of the change
in enthalpy (ΔH) versus temperature (Figure 3.3). ℜth values were then calculated utilizing
Equations 1.10 – 1.16 and results are shown in Table 2.
For Zn2+ binding to the active site of CA, an overall increase in structure is observed,
with approximately 6 residues shown to stabilize as metal ion binding occurs. Cu 2+ binding at the
active site (CuB) shows a similar trend, with an overall increase in structure and approximately 8
residues showing stabilization upon metal ion binding. The differences in the number of residues
that are shown to be stabilizing can be attributed to the differences in coordination modes
between Zn2+ binding, which adopts a tetrahedral coordination mode and Cu2+ that favors a
trigonal bipyramidal binding mode.
In the case of Cu2+ binding at the N-terminal site the ℜth values yield negative results.
We take this to mean that in order for binding to occur, an overall loss of structure of the protein
must first occur. This loss of structure and conversely the degree of negativity seen in the ℜth
values is highly temperature dependent. In case of CuCu-CA the N-terminal binding event yields
a value of approximately 9 residues becoming less structured with copper(II) binding to the CuA
site at 15 °C and a decrease to approximately 5 residues unfolding at the higher temperature of
35 °C. For CuZn-CA, the Cu2+ binding event at the N-terminal site shows the same overall trend,
with approximately 10 residues that destabilize at low temperatures compared to a decrease to
approximately 7 residues destabilizing at higher temperatures
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Figure 3.2

ITC thermogram for Zn2+ binding to apo-CA at 25°C

Panel A) illustrates the raw injection heats for Zn2+ binding to CA and B) the integrated change
in enthalpy (ΔH) with the non-linear regression fit.
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Figure 3.3

Heat capacity determination for CA-metal binding

Heat capacity is determined from the slope of the enthalpy of binding versus temperature. Zn2+ +
Apo-CA is shown in black, Cu2+ + Zn-CA in red, Cu2+ + apo-CA in green and Cu2+ + Cu-CA in
blue.
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Table 3.2

Number of residues organizing upon metal ion binding

Zn2+

Protein
Binding
Site
Apo-CA

Cu2+

Zn-CA

-1.6 ± 0.6

-0.036 ± 0.010

-8

Cu2+

Apo-CA

1.5 ± 0.4

-0.26 ± 0.03

8

Cu2+

Cu-CA

-2.0 ± 0.6

-0.06 ± 0.010

-7

Titrant

-TΔS
(kcal/mol)

ΔCp
(kcal/mol K)

𝕽𝒕𝒉 *

1.7 ± 0.3

-0.22 ± 0.02

6

*Calculated ℜth value errors range from ± 0.7 to ± 1.3, with an average error of ± 0.9
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3.3.2

Guanidine HCl denaturation illustates 𝕽𝒕𝒉 values can be used to estimate changes
in protein stability
To examine how the number of residues that fold upon binding could be linked to protein

stability, GdnHCl denaturation studies were performed on all forms of CA. Each form of CA
(ZnCA, CuZnCA, and CuCuCA) was titrated with increasing amounts of denaturant and the
decrease in intensity at λmax was utilized to calculate the fraction of protein folded at each
titration point. Figure 3.4, panel A illustrates unfolding spectra for CuZn-CA at 25 °C in the
presence of increasing amounts of denaturant. As the denaturant concentration increase, the
protein’s hydrogen bonding network is increasingly disturbed. As this occurs, fluorescent
hydrophobic residues, such as tryptophan, are increasingly subjected to bulk solvent interactions
and their intrinsic fluorescence is quenched. In panel B, the fraction of protein folded at differing
denaturant concentration is shown. This is a indicator of overall stability, as the higher amounts
of denaturant needed to unfold a protein to 50 % can be directly measured. The slope of the
unfolding curve (m-value) is also useful, as the magnitude is directly related to the protein
surface area.36 M-values are reported in Table 3.3. In these studies, Zn-CA was shown to be the
most stable, with apo-CA, CuZn-CA and lastly, CuCu-CA all shown to be increasingly less
stable. This data fits nicely with the values obtained from ITC, where calculated ℜth values show
a decrease in globular structure for CuZn-CA and CuCu-CA, that directly corresponds to a
decrease in stability.
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Figure 3.4

Fluorescence spectra for chemical denaturation of CA

Guandine hydrochloride was used to denature apo-CA. Zn-CA, CuZn-CA- and CuCu-CA. A)
Raw fluorescence spectra at increasing amounts of denaturant and B) calculated protein fraction
folded as a function of denaturant concentration.
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Table 3.3

Calculated m-values for denaturation of apo-CA, Zn-CA, CuZn-CA and CuCu-CA
Protein

m-value

Apo-CA

2.46

Zn-CA

2.24

CuZn-CA

1.98

CuCu-CA

1.72
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CD spectroscopy indicates a loss of globular protein structure when Cu2+ is bound
at the N-terminal site

3.3.3

Circular Dichroism. The CD spectrum of Zn-CA (Figure 3.5, black) shows a profile that
is similar to previously reported spectra.37, 38 In the far-UV region (180-220 nm), there are four
distinct bands, a small positive band at 180 nm, a small positive band at 200 nm, a negative band
at 210 nm and a negative band at 220 nm. The 180 nm and 200 nm bands are characteristically
low in intensity, as has been shown to be the case for proteins with low α-helical content.39 Upon
chelation of the Zn2+ ion, a large decrease in the 180 nm and 200 nm band is observed, as well as
a decrease in the 210 nm band. The 220 nm band is also no longer distinguishable for the apoCA form as well as the CuZn-CA and CuCu-CA forms. Upon addition of either a Zn2+ or Cu2+ in
the active site, as well as a Cu2+ at the N-terminal site, an overall decrease in structure can be
seen, with the 210 nm and 220 nm bands being the most effected. This overall decrease in
structure upon Cu2+ binding at the N-terminal site is in agreement with the 𝕽𝒕𝒉 values calculated
(Table 2). The 𝕽𝒕𝒉 values indicate a global unfolding of ~7 to 8 residues at 25 oC and the CD
data indicate a loss in structure that corroborates this destabilization.
.
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Figure 3.5

CA CD spectra

CD spectra collected for the four form of CA. apo-CA is shown in dark red, Zn-CA in black,
CuZn-CA in red, and CuCu-CA in blue.
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3.4

Discussion and Conclusions
With reaction rates that approach the limit of diffusion, CA has one of the fastest turnover

rates known. This suggests that CA is known to maintain a robust and partially rigid structure,
and this protein also is devoid of intermolecular interactions between subunits that many other
enzymes possess. CAs are also capable of maintaining reasonable activity in less than optimal
conditions. CA activity is only mildly reduced if its native metal Zn2+ is replaced with another
biologically available transition metal, it can withstand a pH of up to 8.9 and retain 70 % of its
activity and with a melting point of 60 oC it is stable at moderately high temperatures.9, 13, 16, 17, 40
Some of this stability is derived from the metal ion coordination, but the role of this metal ion in
protein stabilization is not well established.
Traditionally, metals are considered point charges when they bind to biomacromolecules
that affect only the local environment in close proximity to the coordination site. However,
transition metal ions form Lewis acid/base adducts with some covalency in their bonding
interactions, which is supported by our copper(II) and zinc(II) binding results. Copper(II)
binding to the N-terminal site in CA acts more like a cofactor than a point charge, where there is
a measurable global conformational change associated with the protein stability even in CA that
is historically viewed as non-dynamic. Cu2+ binding at the N-terminal site likely involves the Nterminal amino group and a minimum a histidine side chain (His3 and/or His4), where this
coordination event must lead to the N-terminal region becoming disrupted from its normal
packing.
Interestingly the N-terminal domain has been truncated to form a family of a family of
shortened CAs. The CA missing the first 5 residues, show a globular destabilization of the
protein by 4-5 kcal/mol,41 which is similar to the destabilization recorded for the N-terminal
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Cu2+. Deletion of the first twelve or nineteen N-terminal residues of CA yielded no additional
change in stability.41 This seems to indicate that the first five residues are interacting favorably
with the protein and have a specific impact on the globular stability of the folded unit. We expect
a similar destabilization of the N-terminus is accomplished when Cu2+ binds to this domain.
Zinc(II) binding at the active site of CA shows approximately 6 residues that are
organized. Conversely, copper(II) binding shows an organization of 8 residues upon binding.
The Rth value differences seen could be attributed to the differing coordination modes for
copper(II) and zinc(II) binding, with zinc(II) binding to CA shown to be a pseudotetrahedral
coordination mode, with three histidine residues and one water/hydroxide ion coordinating. In
the case of copper(II) binding to CA, the coordination mode is shown to be trigonal bypyramidal.
This geometry reflects three histidines and two water/hydroxide ions coordinating. However, we
can dive a bit deeper into the metal binding centers, where the H-bonding networks that are
polarized by these coordination events. The active site zinc(II) center can be dissected along each
bound histidine residue. His94 hydrogen bonds through its Nδ to the carbonyl of the sidechain of
Gln92. His96 hydrogen bonds through Nδ through the backbone carbonyl of Asn244, where
Asn244 is hydrogen bonded to the backbone carbonyl of His64. Finally, His119 hydrogen bonds
through its Nδ to the sidechain carbonyl of Glu117. Where the sidechain of Glu117 is hydrogen
bonded to the sidechain and backbone amine of His107, as well as the backbone amine of
Glu106. Metal binding to the active site residues His94, His96 and His119 polarizes these
hydrogen bonding networks, providing stability to the active site, which leads to the strong
enthalpic binding associated with this site. These hydrogen bonding networks do not
dramatically change when copper(II) binds to the active site of CA. The N-terminal region of CA
is significantly disrupted by copper(II) binding, where this region has not been structurally
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characterized. However, the H-bonding networks associated with the coordinating ligands are
highly impacted, which have a direct influence on the flexibility and stability of this region of the
protein. The generality of these trends between the evolutionarily defined active site versus
adventitious binding at the N-terminal site remains to be validated, where these data represents
the first thermodynamic evidence on how conformational entropy effects can give insight into
the nature of these metal ion binding processes.
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Figure 3.6

Active Site hydrogen bonding networks

Hydrogen bonding networks for the active site of CA, including residues His94, His96 and
His119.
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CHAPTER IV
THERMODYNAMICS OF NANOPARTICLE PROTEIN-SURFACE INTERACTIONS
4.1

Introduction
Study of the surface interactions between inorganic nanomaterials and proteins is a

growing field of research that centers on the characterization of specific protein-surface
interactions in an effort to identify the effectiveness of nanomaterial use in drug delivery and
other diagnostic and therapeutic applications.1-7 As more and differing forms of nanomaterials
are used in these types of applications, it has become even more crucial to understand how these
materials interact when directly introduced into the human body. It is currently known that when
introduced into biological systems, and in turn the fluid in those systems, a variety of proteins
have the ability to interact and interfere with the nanomaterial, including either changing the
intended function, facilitating the interaction of the nanomaterial with unintended targets and/or
rendering the nanomaterial functionless. A dynamic and constantly changing biomolecular
corona forms via the noncovalent binding of proteins to the surface of the nanomaterial and this
corona formation, including the individual protein components that make up the corona, have
been shown to alter the fate of the nanomaterial in the body. 1, 8-18 However, insight into the
interaction, interference and the consequences of the corona formation is ultimately limited by
the poor understanding of the specific details of protein-nanomaterial interactions, including (1)
the types of proteins that are more prone to adsorb, (2) the distribution of proteins adsorbed, and
(3) the functionality of the proteins post-adsorption. More importantly, the knowledge of
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specific protein adsorption affinities is a required prerequisite for understanding the nature of the
particular interactions and is often overlooked in favor of studying the competition of protein
binding and/or the mechanism and composition of the formation of the protein corona as a
whole. As another note of interest, many studies favor the use of blood serum or plasma, each
containing thousands of proteins all vying for binding surface on the nanomaterial. 9, 19-23
The use of gold nanoparticles in particular has gained interest due to their unique intrinsic
optical, electrical and surface properties that make them attractive model nanomaterials for the
study of protein surface interactions.2, 24-26 Previous studies have shown binding of proteins to
AuNPs can be monitored via an abundance of methods, including dynamic light scattering
(DLS)19, 27-29, mass spectrometry techniques30-32, zeta potentiometry32, UV-visible
spectroscopy33, 34, Circular Dichroism (CD)35-39, fluorescence spectroscopy27, 37, 40-43, polarized
resonance synchronous spectroscopy (PRS2)44, 45, nuclear magnetic resonance (NMR)46-52,
isothermal titration calorimetry (ITC)53-56, and surface plasmon resonance (SPR).57-59
In light of these reported unique properties, in this study we chose to utilize gold
nanoparticles of two sizes, 15 and 30 nm. We chose 6 proteins, in increasing molecular weights,
and with contrasting structures, charges, and overall morphology. Two abundant serum proteins
were chosen, fibrinogen and serum albumin, as well as a common metalloenzyme, carbonic
anhydrase. A small, very stable IgG binding domain of streptococcal Protein G and a mutant of
this domain were used, that of wtGB3 and K19C GB3 to probe possible thiol formation. To
round out the selection, Glutathione, a very small 3 peptide protein was chosen in which a central
cysteine residue could also lend useful information regarding binding affinities of proteins with
possible thiol formation. UV-Visible spectroscopy was utilized to monitor the plasmonic peak
shifts induced as increasing amounts of protein were titrated into a constant concentration of
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AuNPs. Binding curves were rendered from the maximum peak shift wavelength of each titration
plotted against protein concentration. The binding curves were then fit with two binding models,
the Langmuir model and a modified mass action model.
Polarized resonance synchronous spectroscopy was used to monitor the cross peak
section size change of the AuNP titrations, and binding curves were again generated, with cross
section size in cm2 plotted against protein concentration. DLS measurements were taken on the
1st and 15th titration for each protein and size and charge changes identify at least a single layer
corona formation in the DLS measurements. Lastly, ITC and DSC were employed to
characterize the heat of binding for wtGB3 to 15 nm AuNP and the heat of unfolding for wtGB3
bound to 15 nm AuNPs, respectively.
4.2
4.2.1

Materials and Methods
Nanoparticle Characterization
15 nm and 30 nm nanoparticles were obtained through nanoComposix and used as

provided. AuNP concentration was calculated from the gold percentage and extinction
coefficient obtained via the slope of a standard curve dilution series.
4.2.2

Protein Sample Preparation
Bovine carbonic anhydrase, Bovine serum albumin, fibrinogen and glutathione were

obtained through Sigma. wtGB3 and K19C GB3 were expressed and purified as published
previously.48
4.2.3

UV-visible and PRS2 Titrations
UV-visible titrations were performed on all 6 proteins and with both sizes of AuNPs with

an Olis refurbished 8453 spectrophotometer. 15 individual titrations were prepared with
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increasing protein concentration in the presence of constant nanoparticle concentration. All
titration were allowed to incubate for 1 hour prior to experimentation. PRS2 studies were
performed and scattering cross sections were calculated as previously described on titrations
containing fibrinogen, wtGB3 and Bovine carbonic anhydrase bound to 15 nm AuNPs.44, 45
4.2.4

Calorimetry
ITC experiments were performed with a Microcal VP-ITC at 25 °C. 50 x 10-6 M wtGB3

was loaded into the cell and 400 x 10-9 M 15 nm AuNPs into the syringe. The heat of binding for
thirty injections at 5 uL per injection were collected. DSC experimentation was performed with a
Microcal VP-DSC. 20 10-6 M wtGB3 was thermally unfolded via heating from 15 °C to 95 °C
and non-two state fitting were completed using the Origin software provided with the
instrumentation. Additionally, 20 x 10-6 M wtGB3 bound to 50 x 10-9 M 15 nm AuNPs were
thermally unfolded using the same parameters. Baseline corrections and non-two state fitting
were again completed using the Origin software provided with the instrumentation.
4.2.5

DLS
DLS data were obtained for the 1st and 15th titrations of all proteins on 15 and 30 nm

AuNPs utilizing an Anton Paar Litesizer 500. The 1st samples contained nanoparticles and buffer
only, at 1.85 nM and 0.2 nM for 15 nm and 30 nm AuNPs, respectively. All samples were
allowed to equilibrate for 1 hour at room temperature and then were filtered using an
appropriately sized Anotop syringe filter. The samples were then transferred to a disposable
microcuvette for DLS measurement. The average hydration diameter for each of the samples
were measured using the fitting function standard to the Kalliope software. For each
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measurement, three independently prepared samples were measured and the average value and
standard error of the mean is reported.
4.3
4.3.1

Results and discussion
Appropriate use of model fitting: Langmuir, mass action and McGhee von Hippel
Currently the most widely used fitting model for protein-surface interactions is the

Langmuir model, typically because protein adsorption isotherms inherently resemble a Langmuir
isotherm. Unfortunately, protein absorption behavior diverges from the essential conditions that
must be met in order for a Langmuir fit to be considered appropriate and frequently Kd values
obtained through Langmuir model fitting published in the literature significantly misrepresent
binding constants for protein adsorption.60 Our data suggest this to also be the case, where Kd
values obtained from Langmuir fits are hugely different from Kd values obtained through the
mass action fit.
To test the two models, 15 increasing amounts of the 6 proteins chosen were bound to 15
and 30 nM AuNPs. The number of binding sites, N, were calculated via the radius of hydration
and binding data were fit to the Langmuir model (Equation 4.1) and a modified mass action
model (Equation 4.2). Figure 4.1 illustrates the binding curves obtained and fitting results.

(4.1)

(4.2)
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Each row of Figure 4.1 corresponds to 1 of the proteins, with row A showing the binding
data for glutathione, row B corresponding to wtGB3, row C to K19C GB3, row D to BCA, row E
to BSA, and row F to Fibrinogen. UV-Visible scans were taken (300-800 nm) for each of a series
of 15 titrations (Figure 4.1, columns 1 and 3) and the maximum for each were plotted against
protein concentration to build a binding curve (Figure 4.1, columns 2 and 4). The binding curves
were fit with the Langmuir model (green dashed line), the mass action model (solid blue line),
and then a final refit of the Langmuir model using the parameters obtained from the mass action
fit (red dashed line). The Langmuir model and mass action model yield seemingly similar good
fits, but the Kd values obtained from each are drastically different.
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Table 4.1

RG and max N value at size 15 nm and 30 nm AuNPs for 6 proteins used. N and
RG were calculated via Equation (2) and Equation (3), respectively.

Glutathione
wtGB3
K19C GB3
BCA
BSA
Fibrinogen

RG (Å)
3.75
10.62
10.62
17.17
26.15
109.5

N (15 nm)
1600
199
199
76
33
4
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N (30 nm)
6400
796
796
304
132
16

Figure 4.1

UV-Visible spectra of nanoparticle-protein binding

Scans were taken (300-800 nm) for each of a series of 15 titrations (Figure 1 columns 1 and 3)
and the maximum for each were plotted against protein concentration to build a binding curve
(Figure 1 columns 2 and 4). The binding curves were fit with the Langmuir model (green dashed
line), the mass action model (solid blue line), and then a final refit of the Langmuir model using
the parameters obtained from the mass action fit (red dashed line).
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Dissociation constant values obtained from both fits are shown in Table 4.2. For 15 nm
AuNPs, the difference in the Kd obtained from the Langmuir fit and the mass action fit range
from approximately 30-120 % different and the Langmuir fit errors are seen to be much larger.
For 30 nm AuNPs, the Kd values for the two models are much more similar, with smaller
associated error. Individually, each of the 6 proteins behaved in interesting and different ways.
Glutathione had by-far the largest discrepancy in Kd between the two models, and was found to
favor the 30 nm AuNP binding surface topography. wtGB3 and the mutant K19C has similar
affinity for both sizes of AuNPs and the Cys-containing K19C showed only a slightly larger
affinity for the AuNPs overall. BCA was the only enzyme in the chosen set of proteins, and as a
metalloenzyme it was expected that the Kd would reflect its classification. Other than the
extremely large fibrinogen, BCA by-far has the largest affinity and seemed to favor the smaller
sized 15 nm AuNPs. BSA was consistently seen as an outlier, and this may have to do with the
deformability of BSA once adsorbed to the AuNP surface. 40 Lastly, Fibrinogen was seen to have
the highest affinity for both AuNP sizes and neither model seemed to precisely describe the
adsorption of this protein. This may be due to its size (109.5 angstroms), its shape (long and flat)
or its high prevalence of cysteine residues (58 in total), although all are disulfide bonded.
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Table 4.2

Protein-nanoparticle fit values
15 nm AuNPs

30 nM AuNPs

Kd (Lang) (nM) Kd (MA) (nM) Kd (Lang) (nM)
Glutathione

2167 ± 200

1247 ± 33

Kd (MA) (nM)

1120 ± 242

953 ±65

wtGB3

343 ± 40

98 ± 21

142 ± 8

102 ± 17

K19C GB3

144 ± 25

82 ± 8

109 ± 11

77 ± 5

BCA

70 ± 2

4 ± 1.0

26 ± 4

11 ± 3

BSA

122 ± 16

88 ± 4

156 ± 29

78 ± 10

15 ± 6

6 ± 0.8

2 ± 0.2

1.2 ± 0.2

Fibrinogen

Kd values obtained via fitting maximum peak shift points from UV-Visible spectroscopy data.
Data were fit using a simple Langmuir isotherm to obtain Kd (Lang) in nM, while Kd (MA) in
nM were obtained from the modified mass action fit as seen in Equation 4.
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Scatchard plots were constructed for the complete set of proteins to visualize any
curvature that may be indicative of competition for binding site location, especially toward
saturation where the depletion of binding sites becomes increasingly entropically unfavorable. A
concave-up curvature of the Scatchard plot would indicate a resistance in saturation that could
affect accurate determination of the dissociation constant for the interaction and use of the
McGhee von Hippel model can be used to account for this behavior.61 Figure 6 shows a
representative Scatchard plot for wtGB3 binding to (a) 15 nm AuNPs and (b) 30 nm AuNPs. As
with De Roe et al., no curvature was seen in the Scatchard plots and it was therefore determined
that the McGhee von Hippel model was not necessary to accurately characterize the binding
behavior of the proteins with both 15 and 30 nm AuNPs.62 It is necessary to note that
competition for binding sites, especially at saturating concentrations, may still be a contributing
factor to protein/nanoparticle binding but we are unable to determine this using the methods
utilized in this study.
4.3.2

Two-statedness: Comparison of UV, PRS2 and DLS
Polarized Resonance Synchronous Spectroscopy (PRS2) is a method of scattering and

fluorescence detection, in which both excitation and detection light are linearly polarized.44, 45
In particular, fluorophore on-resonance fluorescence and scattering cross sections for globular
structures can be calculated utilizing UV-vis, fluorescence emission and Raman scattering
experiments. This has been utilized for macromolecule-ligand interactions, specifically for
protein-nanoparticle interactions using polystyrene nanoparticles as an external reference. 44, 45, 63
PRS2 measures linearly polarized light for excitation and detection. Combined with UV-vis
extinction data, scattering cross section sizes in cm2 can be calculated using equation 4.5.
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(4.3)

The scattering cross section of the fluorophore, 𝜎𝑓𝑠𝑐𝑎 , is a function of the concentrations
of polystyrene nanoparticles, 𝐶𝑃𝑆𝑁𝑃 , the concentration of the fluorophore, 𝐶𝑓 , the photon
scattering polarization for the fluorophore, 𝑃𝑓𝑠𝑐𝑎 , the photon scattering polarization for the
𝑠𝑐𝑎
polystyrene nanoparticle, 𝑃𝑃𝑆𝑁𝑃
, and the fluorescence intensities for polystyrene nanoparticles
𝑠𝑐𝑎
𝑠𝑐𝑎
and the fluorophore, 𝐼𝑃𝑆𝑁𝑃,𝑉𝑉
and 𝐼𝑃𝑆𝑁𝑃,𝑉𝑉
, respectively.63 Changes in cross section are indicative

of binding of protein-nanoparticles and/or conformational changes that occur as a result of
macromolecule-ligand binding.
This method was used in combination with UV-Visible extinction data to yield a
scattering cross section size in cm² of a protein-AuNP conjugate system for a set of 15 titrations
with increasing protein concentration and constant AUNP concentrations. It was found that
nanoparticles scatter light in the 500-600 nm region, and the amount of scattering was shown to
increase as increasing amounts of protein were added to the AuNPs. 3 proteins; wtGB3, BCA
and Fibrinogen were bound to 15 nm AuNPS in 15 titrations with increasing amounts of protein
and the calculated scattering cross section was plotted against wavelength (Figure 4.2, panels DF). The normalized maximum for each titration was then plotted against protein concentration
(Figure 4.2, panels A-C) and overlayed with the normalized signal obtained from earlier UVvisible titrations. Data points were connected via a line to guide the eye. Overall, the scattering
cross section signal for wtGB3 and BCA are lower in average value, while for fibrinogen they
begin lower, rise higher and end at approximately equal in value to the UV-visible titration
points. The error calculated for three separate experiments, for both scattering cross section size
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and absorption peak shifts, overlap. Overlay of binding curves built from both the UV extinction
maxima shift and the calculated cross section obtained from PRS2 scattering data are in
quantitative agreement (Figure 4.2). Together, the data suggest two-state binding is sufficient to
describe the initial adsorption process.
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Figure 4.2

PRS2 and UV data comparison

Normalized max wavelength shifts from UV and scattering cross section maxima shift are
overlayed for wtGB3 (A.), BCA (B.) and fibrinogen (C.). Fluorescence scattering spectra are
shown in panels D-F.
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4.3.3

Thermodynamics of adsorption: ITC and DSC
As shown in Figure 4.3, no discernable heat of binding was detected via ITC, even at

high protein concentrations (50 uM wtGB3), leading to the belief that protein-AuNP binding is a
largely entropic process and the heat of GB3 adsorption may be precisely countered by the heat
of citrate ion desorption. Utilizing DSC, thermograms for wtGB3 without AuNPS and with 15
nm AuNPs bound at 50% capacity with wtGB3 was obtained. The DSC thermograms in Figure
4.4B. show one two-state unfolding process for wtGB3 without AuNPS, with a Tm of 72.3 °C
and a ΔG° of 3.5 kcal mol-1. For wtGB3 bound to 15 nm AuNPs, two unfolding transitions are
apparent, the first at a Tm of 55.9 °C with a ΔG° of 2.8 kcal mol-1 and a second Tm at 68.4 °C
with a ΔG° of 1.7 kcal mol-1. Two populations are therefore present when wtGB3 is introduced
to AuNPs, the first population corresponding to protein adsorbed to the nanoparticles and the
second, higher temperature event corresponds to protein in solution.
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Figure 4.3

ITC and DSC Thermograms

400 x 10-9 M AuNPs were titrated into 50 x 10-6 M wtGB3. Raw titration data and titration points
are shown in panel A. 20 uM wtGB3 bound to 400 nM 15 nm AuNPs were heated from 20 °C to
95 °C and panel C shows the unfolding curve of wtGB3 without AuNPs is shown as a dashed
black line and the fit is shown as a dashed orange line. The unfolding curve for wtGB3 bound to
AuNPs is shown as a solid black line, with two distinct unfolding events shown as a solid red
line and a solid blue line. The combination of the two unfolding events results in the overall fit
shown as a solid green line.

121

4.3.4
4.3.4.1

Trends in binding
Nanoparticle size
Nanoparticle size, and therefore curvature, may alter the way in which proteins interact

with the surface of the nanoparticle. Currently, there is a disagreement between research groups
concerning surface curvature altering protein binding, with many groups suggesting curvature
alters the protein binding capacity while others suggest surface curvature is unlinked to protein
binding ability. Our studies suggest that for binding curves fit using the Langmuir isotherm,
apparent binding affinity is markedly different between 15 nm and 30 nm AuNPs, suggesting
that nanoparticle size, and therefore curvature, does indeed play a role. However, using the
modified mass action fit, we see very little difference in binding affinity, save for glutathione,
suggesting curvature plays little if no role. Overall, we find that for very small proteins with very
low binding affinities to begin with, curvature may play some role, but for the other five proteins
tested we see no substantial change in binding capacity as a result in the change in nanoparticle
size. This finding is in line with the results reported by Boulous, et al for bovine serum albumin.
They too found the binding constant to be approximately the same regardless of nanoparticle
shape and size.40 An overall trend is however seen when comparing the Kd obtained from mass
action fits and the calculated radius of gyration for both 15 and 30 nm nanoparticles.
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Figure 4.4

Nanoparticle binding in relation to protein size

Kd for all proteins obtained from mass action fits were plotted against calculated protein radius
of gyration, RG. A relationship between the two for both 15 nm and 30 nm nanoparticles
becomes apparent with BSA being the sole outlier and shown in red.
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4.3.4.2

Thiol formation
The presence of the point mutation, Lys to a Cys at position 19, yields a very modests

decrease in Kd for binding to both 15 and 30 nm AuNPs. This suggests the presence of the
cysteine may aid in stronger binding via a Au-S bond but no definitively stronger affinity to
AuNPs was seen.
4.3.4.3

Changes in hydrodynamic radius
Hydrodynamic radius is a very reliable method to monitor nanoparticle size changes as

protein binding occurs. As shown in Figure 5, changes in the hydrodynamic radius between bare
nanoparticles and each of the six proteins chosen are in line with what is expected to be the
formation of a monolayer on the nanoparticles surface.
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Figure 4.5

Hydrodynamic Diameter (nm)

Changes in the hydrodynamic diameter obtained via DLS measurements for protein binding to
15 nm and 30 nm nanoparticles.
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4.4

Conclusions
We have observed a sizeable difference in the dissociation constant obtained from two

fitting models, a Langmuir model and a mass action derived model. This difference leads us to
believe the commonly used Langmuir model is not the best model to use to describe proteinAuNP surface interactions. By comparison of UV-Visible binding data and PRS2 cross section
data, the binding is shown to be largely two state. Through the use of DSC and ITC, wtGB3
binding is shown to be largely entropic with two populations discernable and comprised of both
AuNP-bound and AuNP-unbound protein in solution. Lastly, nanoparticle size and therefore
curvature, as well as the presence of an accessible cysteine residue for thiolate bond formation
are shown to play no significant part in the initial binding event between the protein and the
AuNP.
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APPENDIX A
SUPPLEMENTARY MATERIAL: RESOLVING DISTINCT MOLECULAR
ORIGINS FOR COPPER EFFECTS ON PAI-1

133

Figure A.1

Copper sensitivity measurements in gel assays on wild-type and H2AH3A PAI-1
in the presence of high salt

Equimolar mixtures of PAI-1 and tPA were prepared after 30 minute incubations of PAI1 with
copper(II) at a wide range of copper(II) concentrations (10-1000 μM, total) 50 mM MOPS, pH
7.4 at 37 °C, containing 250 mM (NH4)2SO4 instead of the standard concentration of 100 mM
(NH4)2SO4 used for these assays (e.g. in Figure 2). Gel densitometry and data analysis were
performed as described under Methods. The percent of PAI-1/tPA complex formation is plotted
as a function of the total Cu(II) concentration. Wild-type and H2AH3A PAI-1 are represented by
squares and open triangles, respectively. Experiments were performed in duplicate.
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Figure A.2

ITC measurements using active wild-type PAI-1

Active wild-type PAI-1 was buffer exchanged into 100 mM MOPS, 250 mM (NH4)2SO4, pH
7.4 at 10 °C using a PD10 column (GE Healthcare), followed by dialysis for 2 hours. A stock
copper(II) solution concentration was verified using atomic absorption spectroscopy. Copper(II)
solutions were made from the ITC buffer dialysate, and then pH corrected to 7.4. Protein and
copper(II)solutions were degassed with spinning for 10 minutes prior to loading PAI-1 at 20
μM, copper(II) 600-900 μM) into the 1.394 mL ITC cell, and syringe, respectively. Copper(II)
from the syringe entered the cell in 4 μL injections, at 240 second intervals, totalling 30
injections. PAI-1 with 650 μM copper(II) datasets are shown with black circles, squares, and
inverted triangles. PAI-1 with 700 μM datasets are shown with light gray triangles, and
diamonds. PAI-1 with 750 μM copper(II) datasets are shown with gray stars, and crosses. PAI-1
with 800uM copper(II) datasets are shown with light gray squares, inverted triangles, and circles.
The data were baseline corrected in NITPIC software, and a global fit to all of the data was
performed using a one-site binding model in SEDPHAT software. The data, global fit and
residuals are represented in GUSSI software via heats of injection (kcal/mol) as a function of
copper(II)/PAI-1 molar ratio.
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Figure A.3

ITC measurements using latent wild-type PAI-1

Latent wild-type PAI-1 was buffer exchanged into 100 mM MOPS, 250 mM (NH4)2SO4, pH
7.4 at 10 °C using a PD10 column (GE Healthcare), followed by dialysis for 2 hours. A stock
copper(II) solution concentration was verified using atomic absorption spectroscopy. Copper(II)
solutions were made from the ITC buffer dialysate, and then pH corrected to 7.4. Protein and
copper(II) ligand solutions were degassed with spinning for 10 minutes prior to loading (PAI-1 at
30uM, copper(II) 600-900 μM) to loading into the 1.394 mL ITC cell, and syringe, respectively.
Copper(II) from the syringe entered the cell in 4 μL injections, at 120 second interval, totalling
45 injections. PAI-1 with 650 μM copper(II) datasets are shown as light gray circles, squares,
and inverted triangles. PAI-1 with 750 μM copper(II) datasets are shown as circles, gray
diamonds, and inverted triangles. The data were baseline corrected in NITPIC software, and a
global fit to all of the data was performed using a two-site, nonsymmetric binding model in
SEDPHAT software. The data, global fit and residuals are represented in GUSSI software via
heats of injection (kcal/mol) as a function of copper(II)/PAI-1 molar ratio.
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Figure A.4

ITC measurements on active H2AH3A PAI-1

Active H2AH3AW175F PAI-1 was buffer exchanged into 100 mM MOPS, 250 mM
(NH4)2SO4, pH 7.4 at 10 °C using a PD10 column (GE Healthcare), followed by dialysis for 2
hours. A stock copper(II)solution concentration was verified using atomic absorption
spectroscopy. Copper(II)solutions were made from the ITC buffer dialysate, and then pH
corrected to 7.4. Protein and copper(II)ligand solutions were degassed with spinning for 10
minutes prior to loading (PAI-1 at 20 μ M, copper(II) 900-1200 μM) to loading into the 1.394
mL ITC cell, and syringe, respectively. Copper(II)from the syringe entered the cell in 4 μL
injections, at 240 second interval, totaling 30 injections. PAI-1 replicates with 1200 μM
copper(II) datasets are shown as gray circles and squares. PAI-1 replicates with 1350 μM
copper(II) datasets are shown as light gray inverted triangles and triangles. The data were
baseline corrected in NITPIC software, and a global fit to all of the data was performed using a
one-site binding model in SEDPHAT software. The data, global fit and residuals are represented
in GUSSI software via heats of injection (kcal/mol) as a function of copper(II)/PAI-1 molar
ratio.
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Figure A.5

ITC measurements on latent H2AH3A PAI-1

Latent H2AH3AW175F PAI-1 was buffer exchanged into 100 mM MOPS, 250 mM
(NH4)2SO4, pH 7.4 at 10 °C using a PD10 column (GE Healthcare), and dialysis for 2 hours. A
stock copper(II)solution concentration was confirmed using atomic absorption spectroscopy.
Copper(II)solutions were made from the ITC buffer dialysate, and then pH corrected to 7.4.
Protein and copper(II)ligand solutions were degassed with spinning for 10 minutes prior to
loading (PAI-1 at 20 μM, copper(II) 900-1200 μM) to loading into the 1.394 mL ITC cell, and
syringe, respectively. Copper(II)from the syringe entered the cell in 4 μL injections, at 240
second interval, totalling 30 injections. PAI-1 with 1050 μM copper(II) datasets are shown as
gray circles. PAI-1 with 1200 μM copper(II) replicate datasets are shown as light gray squares,
inverted triangles, and triangles. The data were baseline corrected in NITPIC software, and a
global fit to all of the data was performed using a one-site binding model in SEDPHAT software.
The data, global fit and residuals are represented in GUSSI software via heats of injection
(kcal/mol) as a function of copper(II)/PAI-1 molar ratio.
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SUPPLEMENTARY MATERIAL: IMPACT OF THERMAL STABILITY OF PROTEINS
UPON CUPRIC ION BINDING: A CASE STUDY OF COPPER(II) BINDING
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Table B.1

Titrant

Zn2+

Cu2+

Cu2+

Cu2+

The pH and buffer independent thermodynamic values obtained through ITC
experiments
Protein

Apo-CA

Zn-CA

Apo-CA

Cu-CA

Temp
(K)

Ka

ΔG
(kcal/mol)

ΔH
(kcal/mol)

-TΔS
(kcal/mol K)

288

5.9(±1.2)x109

-12.9 ± 0.7

-12.0 ± 0.4

-0.9 ± 0.4

293

4.4(±0.8)x109

-12.9 ±0.6

-13.2 ± 0.3

0.3 ± 0.4

298

3.6(±1.0)x109

-13.0 ±0.7

-14.7 ± 0.7

1.7 ± 0.3

303

7.7(±0.5)x109

-13.7 ±0.4

-15.4 ± 0.6

1.7 ± 0.2

308

1.0(±0.3)1010

-14.1 ±0.4

-16.4 ± 0.4

2.3 ± 0.3

288

2.0(±0.7)109

-13.6 ±0.5

-9.4 ± 0.3

-4.2 ± 0.5

293

1.3(±1.1)108

-12.2 ±0.4

-9.6 ± 0.6

-2.6 ± 0.6

298

2.4(±0.9)107

-11.4 ±0.4

-9.8 ± 0.6

-1.6 ± 0.6

303

1.9(±0.9)106

-10.1 ±0.2

-10.0 ± 0.4

-0.1 ± 0.4

308

9.1(±0.6)105

-9.8 ±0.3

-10.1 ± 0.3

0.3 ± 0.2

288

6.0 (±1.0)105

-7.6 ± 0.6

-6.1 ± 0.3

-1.5 ± 0.4

293

4.7(±0.3)105

-7.6 ± 0.5

-7.1 ± 0.4

-0.5 ± 0.5

298

3.3(±0.7)105

-7.5 ±0.6

-9.0 ± 0.5

1.5 ± 0.4

303

3.0(±0.6)105

-7.6 ±0.4

-9.9 ± 0.5

2.3 ± 0.3

308

2.8(±0.9)106

-9.1 ±0.2

-11.1 ± 0.5

2.0 ± 0.3

288

6.9(±1.3)1010

-14.3 ±0.4

-8.9 ± 0.3

-5.4 ± 1.0

293

3.1(±0.9)109

-12.7 ±0.5

-9.1 ± 0.5

-3.6 ± 0.8

298

3.6(±0.4)108

-11.7 ±0.4

-9.7 ± 0.6

-2.0 ± 0.6

303

5.5(±0.6)107

-10.7 ±0.4

-9.7 ± 0.6

-1.0 ± 0.4

308

2.8(±0.8)106

-9.1 ±0.3

-10.1 ± 0.4

1.0 ± 0.4
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Table B.2

Calculated ℜ𝑡ℎ values

Titrant

Zn2+

Cu2+

Cu2+

Cu2+

Protein

Apo-CA

Zn-CA

Apo-CA

Cu-CA

Temp

-TΔS

ΔCp

(K)

(kcal/mol)

(kcal/mol K)

288

-0.9 ± 0.4

-0.22 ± 0.02

6

293

0.3 ± 0.4

-0.22 ± 0.02

6

298

1.7 ± 0.3

-0.22 ± 0.02

6

303

1.7 ± 0.2

-0.22 ± 0.02

5

308

2.3 ± 0.3

-0.22 ± 0.02

5

288

-4.2 ± 0.5

-0.036 ± 0.010

-10

293

-2.6 ± 0.6

-0.036 ± 0.010

-9

298

-1.6 ± 0.6

-0.036 ± 0.010

-8

303

-0.1 ± 0.4

-0.036 ± 0.010

-7

308

0.3 ± 0.2

-0.036 ± 0.010

-7

288

-1.5 ± 0.4

-0.26 ± 0.03

8

293

-0.5 ± 0.5

-0.26 ± 0.03

8

298

1.5 ± 0.4

-0.26 ± 0.03

8

303

2.3 ± 0.3

-0.26 ± 0.03

8

308

2.0 ± 0.3

-0.26 ± 0.03

7

288

-5.4 ± 1.0

-0.06 ± 0.010

-9

293

-3.6 ± 0.8

-0.06± 0.010

-8

298

-2.0 ± 0.6

-0.06 ± 0.010

-7

303

-1.0 ± 0.4

-0.06 ± 0.010

-6

308

1.0 ± 0.4

-0.06 ± 0.010

-5

141

𝕽𝒕𝒉 *

Figure B.1

Apo-CA GdnHCl denaturation fluorescence spectra

Apo-carbonic anhydrase spectra showing the decrease in flourescence intensity as denaturant
concentration is increased.
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Figure B.2

CuZn-CA GdnHCl denaturation fluorescence spectra

CuZn-carbonic anhydrase spectra showing the decrease in flourescence intensity as denaturant
concentration is increased.
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Figure B.3

CuCu-CA GdnHCl denaturation fluorescence spectra

CuCu-carbonic anhydrase spectra showing the decrease in flourescence intensity as denaturant
concentration is increased.
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Figure B.4

ITC Thermogram for CuCu-CA binding at 15°C

ITC thermogram of CuCu-CA binding illustrating two distinct binding events. Concentration
were approximately 70 micromolar CA and 2 mM copper(II).
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